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Background: Our Cochrane review of selective serotonin inhibitors for stroke recovery indicated
that fluoxetine may improve functional recovery, but the trials were small and most were at high
risk of bias.
Objectives: The Fluoxetine Or Control Under Supervision (FOCUS) trial tested the hypothesis that
fluoxetine improves recovery after stroke.
Design: The FOCUS trial was a pragmatic, multicentre, parallel-group, individually randomised,
placebo-controlled trial.
Setting: This trial took place in 103 UK hospitals.
Participants: Patients were eligible if they were aged ≥ 18 years, had a clinical stroke diagnosis, with
focal neurological deficits, between 2 and 15 days after onset.
Interventions: Patients were randomly allocated 20 mg of fluoxetine once per day or the matching
placebo for 6 months via a web-based system using a minimisation algorithm.
Main outcome measures: The primary outcome was the modified Rankin Scale at 6 months. Patients,
carers, health-care staff and the trial team were masked to treatment allocation. Outcome was assessed
at 6 and 12 months after randomisation. Patients were analysed by their treatment allocation as specified
in a published statistical analysis plan.
Results: Between 10 September 2012 and 31 March 2017, we recruited 3127 patients, 1564 of whom
were allocated fluoxetine and 1563 of whom were allocated placebo. The modified Rankin Scale score
at 6 months was available for 1553 out of 1564 (99.3%) of those allocated fluoxetine and 1553 out of
1563 (99.4%) of those allocated placebo. The distribution across modified Rankin Scale categories at
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6 months was similar in the two groups (common odds ratio adjusted for minimisation variables
0.951, 95% confidence interval 0.839 to 1.079; p = 0.439). Compared with placebo, patients who were
allocated fluoxetine were less likely to develop a new episode of depression by 6 months [210 (13.0%)
vs. 269 (16.9%), difference –3.78%, 95% confidence interval –1.26% to –6.30%; p = 0.003], but had
more bone fractures [45 (2.9%) vs. 23 (1.5%), difference 1.41%, 95% confidence interval 0.38% to
2.43%; p = 0.007]. There were no statistically significant differences in any other recorded events at
6 or 12 months. Health economic analyses showed no differences between groups in health-related
quality of life, hospital bed usage or health-care costs.
Limitations: Some non-adherence to trial medication, lack of face-to-face assessment of neurological
status at follow-up and lack of formal psychiatric diagnosis during follow-up.
Conclusions: 20 mg of fluoxetine daily for 6 months after acute stroke did not improve patients’
functional outcome but decreased the occurrence of depression and increased the risk of fractures.
These data inform decisions about using fluoxetine after stroke to improve functional outcome or
to prevent or treat mood disorders. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY)
(Australasia/Vietnam) and Efficacy oF Fluoxetine – a randomisEd Controlled Trial in Stroke (EFFECTS)
(Sweden) trials recruited an additional 2780 patients and will report their results in 2020. These three
trials have an almost identical protocol, which was collaboratively developed. Our planned individual
patient data meta-analysis will provide more precise estimates of the effects of fluoxetine after stroke
and indicate whether or not effects vary depending on patients’ characteristics and health-care setting.
Trial registration: Current Controlled Trials ISRCTN83290762.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 22. See the NIHR Journals Library website for further project information. The Stroke
Association (reference TSA 2011101) funded the start-up phase.
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Plain English summary
Fluoxetine, sometimes referred to by the drug company name Prozac, has been used for manyyears to treat people who are depressed, including after a stroke. However, studies have suggested
that treatment with fluoxetine started soon after a stroke might improve patients’ physical recovery.
The Fluoxetine Or Control Under Supervision (FOCUS) trial recruited 3127 volunteers who had had
a stroke within the previous 2 weeks from 103 UK hospitals between 2012 and 2017. Participants
were randomly allocated to take a 6-month course of fluoxetine or an identical placebo capsule
containing no fluoxetine. They were followed up at 6 months and 12 months after recruitment.
Patients completed questionnaires that indicated how much they had recovered, and also measured
their mood, fatigue and quality of life. The results of the trial showed that the physical recovery of
patients was very similar in both groups. This indicates that fluoxetine does not improve physical
outcomes of stroke patients. However, participants receiving fluoxetine were less likely to develop
depression after the stroke but once the fluoxetine was stopped these effects on mood disappeared.
Unfortunately, patients on fluoxetine were slightly more likely to fall and fracture a bone than those
on placebo. The FOCUS trial is the first of three large randomised controlled trials testing fluoxetine
in stroke patients to be completed. The FOCUS trial results suggest that patients with stroke should
not routinely be treated with fluoxetine.
The other two trials will give us further information about the effects of fluoxetine after stroke and
whether or not its effects differ between countries or ethnic groups.
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Scientific summary
Background
Each year worldwide, stroke affects about 9 million people for the first time, and results in about
6.5 million people living with disability.
Fluoxetine, a selective serotonin reuptake inhibitor, is used to treat depression and emotional lability
after stroke. Many clinical and pre-clinical studies have suggested that selective serotonin reuptake
inhibitors might improve outcome after stroke through a range of mechanisms, which include enhancing
neuroplasticity and promoting neurogenesis. In 2011, the FLuoxetine for motor recovery After acute
ischaeMic strokE (FLAME) trial indicated that fluoxetine enhanced motor recovery [Chollet F, Tardy J,
Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic
stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123–30]. A subsequent
Cochrane systematic review of selective serotonin reuptake inhibitors for stroke recovery identified
52 randomised controlled trials of selective serotonin reuptake inhibitors versus control in a total
of 4060 patients [Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML.
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev
2012;11:CD009286]. This review suggested that selective serotonin reuptake inhibitors may reduce
post-stroke disability, but greater effects were seen if studies with increased risk of bias were retained
and patients with depression were included. Although promising, these data were not sufficiently
compelling to alter stroke treatment guidelines or to alleviate concerns that any possible benefits of
fluoxetine might be offset by serious adverse reactions.
Objectives
Primary question
1. Does the routine early administration of fluoxetine (20 mg once per day) for 6 months after an
acute stroke improve patients’ functional outcome?
Secondary questions
2. If fluoxetine improves functional outcome, does any improvement persist after treatment
is stopped?
3. Among patients with acute stroke:
i. If there is motor impairment, does fluoxetine improve patients’ motor function and does any
improvement persist after treatment is stopped?
ii. If there is communication impairment, does fluoxetine improve patients’ communication function
and does any improvement persist after treatment is stopped?
iii. If there are impairments that preclude the formal assessment of post-stroke mood, does
fluoxetine improve patients’ functional outcomes?
iv. Does fluoxetine improve patients’ outcome with respect to mood, fatigue, cognition, health-related
quality of life or participation and does any improvement persist after treatment is stopped?
v. Does fluoxetine reduce the cost of health care over the first year?
vi. Does fluoxetine increase the risk of serious adverse events?
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xxiii
Methods
The Fluoxetine Or Control Under Supervision (FOCUS) trial was a pragmatic, multicentre, parallel-group,
double-blind, placebo-controlled trial that was conducted in the UK with a centralised randomisation
system to allocate individuals to treatment in a 1 : 1 ratio.
Patients
Inclusion criteria:
l Adults aged ≥ 18 years.
l A clinical diagnosis of acute stroke with brain imaging compatible with intracerebral haemorrhage or
ischaemic stroke including a normal brain scan.
l Randomisation between 2 and 15 days after stroke onset.
l A persisting focal neurological deficit at the time of randomisation and severe enough to warrant
6 months of treatment from the patient’s or carer’s perspective.
Exclusion criteria:
l Subarachnoid haemorrhage except where secondary to a primary intracerebral haemorrhage.
l Unlikely to be available for follow-up for the following 12 months.
l Unable to speak English and no close family member available to help with follow-up.
l Other life-threatening illness (e.g. advanced cancer) that would make 12-month survival unlikely.
l History of epileptic seizures.
l History of allergy to fluoxetine.
l Contraindications to fluoxetine, including hepatic impairment (alanine aminotransferase > 3 × upper
normal limit) and renal impairment (creatinine level of > 180 µmol/l).
l Pregnancy or breastfeeding, and women of childbearing age not taking contraception.
l Previous drug overdose or attempted suicide.
l Already enrolled into a controlled trial of an investigational medicinal product.
l Current or recent (within the last month) depression treated with a selective serotonin reuptake
inhibitor, although patients were eligible if depressed or taking an antidepressant other than a
selective serotonin reuptake inhibitor or a monoamine oxidase inhibitor.
l Current or recent use of medications that have a potentially serious interaction with fluoxetine.
Patients, or a proxy if patients had mental incapacity, provided written informed consent that covered
accessing their medical records and routinely collected NHS data.
Randomisation and blinding
The clinician entered the patient’s baseline data into a secure web-based randomisation system.
After the data were checked for completeness and consistency, the system generated a unique study
identification number and a treatment pack number that corresponded to fluoxetine or placebo. A
minimisation algorithm was used to achieve optimum balance (ratio 1 : 1) between treatment groups
for the following factors: delay since stroke onset (2–8 vs. 9–15 days), computer-generated prediction
of 6-month outcome (probability of modified Rankin Scale of 0–2 was ≤ 0.15 vs. > 0.15 based on the
six simple variable model) and presence of a motor deficit or aphasia (according to the National
Institutes of Health Stroke Scale). The system also incorporated an element of randomisation over and
above the minimisation algorithm, so that it allocated patients to the treatment group that minimised
imbalance between the groups with a probability of 0.8 rather than 1.0.
The patients, their families, the health-care teams including the pharmacists, the staff in the
co-ordinating centre and anyone involved in outcome assessments were blinded to the treatment
allocation, as a placebo capsule was used.
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Allocated treatments
The allocated treatments were 20 mg of fluoxetine once per day or placebo for 6 months. Patients
were supplied with 186 capsules. We measured adherence to the study medication in several ways,
but our primary measure of adherence was the best estimate of the interval between the first and the
last dose based on all of the information available.
Primary outcome
The primary outcome was functional status, measured according to the modified Rankin Scale at the
6-month follow-up. We used the simplified modified Rankin Scale questionnaire delivered by postal
questionnaire to determine modified Rankin Scale scores. Among those without a complete postal
questionnaire, telephone interview was undertaken for any further clarification, completion of missing
items or the whole questionnaire.
Secondary outcomes at 6 and 12 months
l Survival.
l Modified Rankin Scale score at 12 months.
l Health status measured using the Stroke Impact Scale for each of nine domains: arm, hand, leg and
foot strength; hand function; mobility; communication and understanding; memory and thinking;
mood and emotions; daily activities; participation in work, leisure and social activities; and overall
rating of recovery on a visual analogue scale.
l Mood assessed with the Mental Health Inventory.
l Fatigue assessed with the vitality subscale of the Short Form questionnaire-36 items.
l Health-related quality of life measured with the EuroQol-5 Dimensions, five-level version, to
generate utilities.
Safety outcomes
Safety outcomes were systematically recorded, including:
l recurrent stroke including ischaemic and haemorrhagic strokes
l acute coronary syndromes
l epileptic seizures
l hyponatraemia (Na+ < 125 mmol/l)
l upper gastrointestinal bleeding
l other major bleeds (lower gastrointestinal, extracranial, subdural, extradural and subarachnoid)
l poorly controlled diabetes including hyperglycaemia (> 22 mmol/l) and symptomatic hypoglycaemia
l falls resulting in injury
l bone fractures
l new episode of depression during the trial (including a diagnosis made by the treating clinician and
initiation of a new antidepressant prescription)
l attempted suicide or self-harm.
Follow-up
The recruiting hospital staff monitored early adherence, identified adverse events in hospital and
completed the follow-up form at hospital discharge or death in hospital. The national co-ordinating
centre staff followed up the patients at 6 and 12 months to measure the primary and secondary
outcomes. Data on safety outcomes and medications were also collected from the patients’ general
practitioners at 6 and 12 months. Adherence to medication was measured by clinician and patient
reports and returned capsule counts.
Sample size
We aimed to recruit at least 3000 patients to identify a treatment effect size of fluoxetine that
we thought would be important to patients and health and social care services, and would justify a
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xxv
6-month course of treatment. The FOCUS trial had 90% power to identify an increase in the
proportion of patients with good outcomes (i.e. modified Rankin Scale of 0–2) from 39.6% to 44.7%
(i.e. absolute difference 5.1%), based on an ordinal analysis expressed as a common odds ratio of 1.23.
Statistical analyses
For our primary outcome, we carried out an ordinal analysis expressing the result as a common odds
ratio and 95% confidence interval adjusted using ordinal logistic regression for the variables in the
minimisation algorithm. We performed Cox proportional hazards modelling to analyse the effect of
treatment on survival to 12 months, also adjusting for the variables included in our minimisation
algorithm. We compared the frequency of outcome events by calculating the differences in proportions
between treatment groups with their 95% confidence intervals and p-values. We present the median
scores on the Stroke Impact Scale, Mental Health Inventory – 5 questions, vitality subscale of the Short
Form questionnaire-36 items and EuroQol-5 Dimensions, five-level version, with the interquartile
ranges and p-value derived using non-parametric methods (Mann–Whitney U-test). For all of these
scales, higher values represent better outcomes.
Prespecified subgroup analyses were the effect of treatment allocation on the primary outcome
subdivided by key baseline variables described in our published statistical analysis plan, including
probability of being alive and independent (0 to ≤ 0.15 vs. > 0.15 to 1); delay from stroke onset to
randomisation (2–8 days vs. 9–15 days), motor deficit (present or absent) or aphasia (present or
absent), pathological type of stroke (ischaemic vs. haemorrhagic) and age (≤ 70 years vs. > 70 years);
ability to consent for themselves (yes or no); and whether or not mood was assessable at baseline
and whether or not the patient was depressed at baseline. Subgroup analyses were undertaken by
observing the change in log-likelihood when the interaction between the treatment and the subgroup
was added into a logistic regression model. Statistical analyses were conducted using SAS® version 9.4
(SAS Institute Inc., Cary, NC, USA) (SAS and all other SAS Institute Inc. product or service names are
registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates
USA registration).
The protocol was given ethics approved by the Scotland A Research Ethics Committee (reference
21/12/2011). The study was jointly sponsored by the University of Edinburgh and NHS Lothian.
The full protocol is available online (see www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#).
Results
Between 10 September 2012 and 31 March 2017, 103 UK hospitals enrolled 3127 patients; 1564
were allocated fluoxetine and 1563 were allocated placebo. The baseline characteristics of the two
treatment groups were well balanced and were fairly similar to the characteristics of unselected stroke
patients who were admitted to UK hospitals.
The primary measure of adherence was available in 1417 (91%) patients in each group. The median
duration of treatment was 185 days (interquartile range 149–186 days) in the fluoxetine group and
183 days (interquartile range 136–186 days) in the placebo group. About two-thirds of patients took
the study medication for at least 150 days.
Our primary outcome was available in 1553 out of 1564 (99.3%) patients allocated to fluoxetine and
1553 out of 1563 (99.4%) patients allocated to placebo at 6 months. An ordinal comparison of the
distribution of patients across the modified Rankin Scale at 6 months, adjusted for variables included in
the minimisation algorithm, was similar in the two groups (common odds ratio 0.951, 95% confidence
interval 0.839 to 1.079; p = 0.439), where a common odds ratio in favour of placebo is < 1.0. The
unadjusted analysis provided similar results (common odds ratio 0.961, 95% confidence interval
0.848 to 1.089; p = 0.531).
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There were no statistically significant interactions between the prespecified subgroups and the effect of
treatment on the primary outcome. We investigated the effect of fluoxetine on our primary outcome in
subgroups defined by their meeting the eligibility criteria and being adherent to the study medication to
different degrees. There is no trend towards greater benefit in those with greater adherence.
Those allocated fluoxetine were less likely than those allocated placebo to be diagnosed with a new
episode of depression during the trial [n = 210 (13.0%) fluoxetine vs. n = 269 (16.9%) placebo, difference
in proportion –3.78%, 95% confidence interval –1.26% to –6.30%; p = 0.003], and had better mood
measured on Mental Health Inventory – 5 questions at 6-month follow-up (median score 76 fluoxetine
vs. 72 placebo; p = 0.010). Those allocated fluoxetine had an increased risk of fractures compared with
those allocated placebo [n = 45 (2.9%) fluoxetine vs. n = 23 (1.5%) placebo, difference in proportion
1.41%, 95% confidence interval 0.38% to 2.43%; p = 0.007]. There were no statistically significant
differences in any other secondary outcomes at 6 months, including any of the nine domains of the
Stroke Impact Scale, the vitality subscale of Short Form questionnaire-36 items and the EuroQol-5
Dimensions, five-level version, or other recorded safety outcomes.
The difference in the cumulative number of patients diagnosed with a new episode of depression over the
12 months between the two treatment groups was no longer statistically significant and the difference in
Mental Health Inventory – 5 questions scores at 6 months was not sustained at 12 months. There were
no statistically significant differences between treatment groups in any other secondary outcomes at
12 months, including survival (hazard ratio 0.929, 95% confidence interval 0.756 to 1.141; p = 0.482).
We assessed the effect of treatment among participants in the subgroup with motor deficit at baseline
(n = 2722) who had a modified Rankin Scale score at 6 months (n = 2702), but found no evidence of an
effect on the modified Rankin Scale (p = 0.217). Of the 2722 participants who had a motor deficit at
baseline, 2438 had a motor score outcome [fluoxetine median 48.43 (interquartile range 24.98–78.84)
vs. placebo median 52.66 (interquartile range 25.28–77.22); p = 0.471]. In addition, of the 906 patients
with aphasia at baseline, 899 had a modified Rankin Scale score at 6 months and 794 had a Stroke
Impact Scale communication domain score at 6 months. There was little difference in the modified
Rankin Scale or Stroke Impact Scale communication scores [fluoxetine median 64.29 (interquartile
range 32.14–89.29) vs. placebo median 64.29 (interquartile range 35.71–89.29); p = 0.497]. Our health
economic analyses showed no difference between the treatment groups in health-related quality of
life, use of health-care resources or health-care costs during the first year of follow-up.
Conclusions
The FOCUS trial provides reliable answers to our research questions:
1. Does the routine early administration of fluoxetine (20 mg once per day) for 6 months after an
acute stroke improve patients’ functional outcome? Answer: no.
2. Does any functional improvement persist after treatment is stopped? Answer: not relevant because
no functional improvement was identified during treatment.
3. Among patients with acute stroke –
i. If there is motor impairment, does fluoxetine improve patients’ motor function and does any
improvement persist after treatment is stopped? Answer: no, it does not appear to but the trial
was not powered for this subgroup analysis.
ii. If there is communication impairment, does fluoxetine improve patients’ communication function
and does any improvement persist after treatment is stopped? Answer: no, it does not appear to
but the trial was not powered for this subgroup analysis.
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iii. If there are impairments that preclude the formal assessment of post-stroke mood, does
fluoxetine improve patients’ functional outcomes? Answer: no, it does not appear to, but the trial
was not powered for this subgroup analysis.
iv. Does fluoxetine improve patients’ outcome with respect to mood, fatigue, cognition, health-
related quality of life or participation and does any improvement persist after treatment is
stopped? Answer: probably; it reduced the incidence of new episodes of depression in the first
6 months, and patients’ mood at 6 months was better than for those taking placebo. However,
similar results might be seen if fluoxetine simply stopped mood deteriorating. The differences in
mood did not persist once the fluoxetine was stopped.
v. Does fluoxetine reduce the cost of health care over the first year? Answer: no, it does not appear
to, but the trial was not powered for this outcome.
vi. Does fluoxetine increase the risk of serious adverse events? Answer: yes, it increased the risk of
bone fractures.
These data will inform decision-making about the use of fluoxetine after stroke, whether aimed at
improving functional outcome or preventing or treating mood disorders. Ongoing trials and a planned
individual patient data meta-analysis are planned to confirm or refute a more modest benefit, either
overall or in particular subgroups, and to provide more precise estimates of any harms.
Trial registration
This trial is registered as ISRCTN83290762.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 22.
See the NIHR Journals Library website for further project information. The Stroke Association
(reference TSA 2011101) funded the start-up phase.
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Chapter 1 Introduction
The burden of stroke
Approximately 130,000 people have a stroke each year in the UK and, even with acute treatments,
about 50% of survivors will have long-term residual disability.1 This places a huge burden on health and
social services and informal carers. Although more can be done to implement treatments that we know
are effective (e.g. the more widespread provision of thrombolysis and thrombectomy and more rapid
access to stroke units), there is still an urgent need to identify new treatments that might reduce
neurological impairments, disability and dependency after stroke. One promising intervention that
needs to be tested is a widely used antidepressant drug, fluoxetine, which is a selective serotonin
reuptake inhibitor (SSRI).
Serotonin reuptake inhibitors in animal models
In animals, SSRIs have several potentially beneficial effects on both normal and diseased brains. First,
they have a neurotrophic effect. Neurotrophins are involved in embryogenesis and organogenesis,
control neural plasticity in adults, regulate synaptic activity and neurotransmitter synthesis and are
essential for the regeneration of nerves.2 Adult neurogenesis is generally restricted to the subependymal
cells of the ventricular system and the subgranular zone of the dentate gyrus in the hippocampus.3
SSRI antidepressants increase neurogenesis and expression of neurotrophic/growth factors in the
adult hippocampus,4 which is likely to account for the behavioural benefits of antidepressants in
animals.5 Importantly, several studies have shown that migration of new neurones to damaged areas
of brain may occur,6 and that neurogenesis may also occur in areas of damaged brain in patients who
have had ischaemic stroke.7 Second, fluoxetine may have a neuroprotective effect associated with its
anti-inflammatory effect (e.g. repression of microglia activation)8 and enhancement of specific protein
expression (e.g. hypoxia-inducible factor-1 alpha and heme oxygenase-1).9 Third, SSRIs can indirectly
affect the adrenergic system through the upregulation of beta-1 receptors.10
Selective serotonin reuptake inhibitors and motor function in humans
In healthy humans, functional magnetic resonance imaging studies have demonstrated that fluoxetine
can modulate cerebral motor activity.11 In eight patients who had a pure motor stroke who were given
fluoxetine, there was hyperactivation in the ipsilesional primary motor cortex during a motor task;
moreover, fluoxetine significantly improved motor skills in the affected side.12 In a small-scale randomised
trial of patients who had a unilateral stroke, the administration of citalopram, another SSRI, was associated
with a significant improvement in neurological status, as measured with the National Institutes of Health
Stroke Scale (NIHSS),13 and a decrease of motor excitability over the unaffected hemisphere, as measured
by transmagnetic stimulation.14 Zittel et al.15 investigated the effects of a single dose of 40mg of citalopram
in eight chronic stroke patients; dexterity was significantly improved. In a trial of 52 hemiplegic patients
who were randomly allocated to receive one of three treatments (20 mg/day of fluoxetine vs. 150 mg/day
of maprotiline vs. placebo) for 3 months against a background of physical therapy, those allocated to
receive fluoxetine demonstrated the greatest recovery from disability.16
The FLuoxetine for motor recovery After acute ischaeMic strokE (FLAME) trial17 evaluated the effects of
SSRIs on motor recovery after stroke. This double-blind, placebo-controlled, multicentre trial randomised
118 patients who had an ischaemic stroke and unilateral motor weakness to receive either 20 mg of
fluoxetine daily or placebo for 3 months. At day 90, the improvement in the Fugl-Meyer Assessment
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
1
Motor Score from baseline was significantly greater in the fluoxetine group [57 patients, adjusted mean
34.0, 95% confidence interval (CI) 29.7 to 38.4] than in the placebo group (56 patients, adjusted mean
24.3, 95% CI 19.9 to 28.7) (p = 0.003). In a post hoc analysis, the frequency of independent patients
[modified Rankin Scale (mRS) of 0–2]18 was significantly higher in the fluoxetine group than in the
placebo group (26.3% vs. 8.9%; p = 0.015), although there were no significant differences at other cut-off
points. The small sample size limits the study’s generalisability. All patients also received physiotherapy
(of unknown intensity), so we do not know whether or not fluoxetine on its own, or with less intense
physiotherapy, would also be effective. Importantly, we also do not know whether or not any benefits of
fluoxetine persist beyond the treatment period and whether or not fluoxetine might improve outcome
in stroke patients without motor deficits. Nevertheless, these promising but inconclusive results clearly
justify further larger trials in patients who have motor deficits.
Might selective serotonin reuptake inhibitors be of benefit in recovery of
non-motor aspects of stroke?
Several small studies have suggested that fluoxetine might have other neurological benefits (e.g. increased
activation of agonist and antagonist muscles in paretic arms after stroke,19 and improvements in executive
function after stroke20). We do not know whether or not these beneficial effects of antidepressants are
independent of their antidepressant effect.21
In people with depression, SSRIs modulate the hyperactivity of the hypothalamic pituitary axis (HPA).22
After stroke, activation of the HPA occurs, resulting in hypercortisolism. Hypercortisolism is associated
with the development of delirium after stroke and also predicts worse long-term outcome.23 Thus,
SSRIs might, by attenuating the hypercortisolism that is present after stroke, improve outcomes,
including cognition.
Systematic review of effects of fluoxetine on post-stroke outcomes
In 2011, when the Fluoxetine Or Control Under Supervision (FOCUS) trial was being planned,
a recent systematic review of randomised controlled trials (RCTs) testing whether or not a course of
treatment with fluoxetine started shortly after stroke onset might improve function and prevent post
stroke depression identified six RCTs published before December 2009, which together randomised
385 patients.24 Meta-analysis demonstrated that fluoxetine helped recovery in neurological function
(weighted mean difference –4.72, 95% CI –8.31 to –1.13), improved independence in activities of
daily living (weighted mean difference –8.04, 95% CI –13.40 to –2.68) and reduced the incidence of
post-stroke depression [odds ratio (OR) 0.25, 95% CI 0.11 to 0.56]. A Cochrane review of selective
serotonin receptor antagonists in stroke25 subsequently identified 56 trials comparing SSRIs with
a control intervention (e.g. usual care or placebo), which were given in the first year after stroke.
Fifty-two trials (4059 participants) reported data that could be included in the meta-analyses.
Of these 52 trials, 28 used fluoxetine and 31 recruited patients within 3 months of stroke onset.
The meta-analyses demonstrated beneficial effects of SSRIs on dependency, disability, neurological
deficit, depression and anxiety at the end of treatment. There were benefits even in patients without
depression at recruitment. However, there was substantial heterogeneity in the estimates of effect
sizes; sensitivity analyses suggested that methodological limitations of many of the included trials may
have led to overestimation of effect sizes and there was an excess of gastrointestinal side effects in
patients receiving a SSRI.25 Furthermore, most trials excluded people with cognitive impairment and
aphasia, and only eight trials followed patients up after treatment had been discontinued.
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Why choose fluoxetine?
There are many SSRI antidepressant medications available. We chose to evaluate fluoxetine because
it is one of the most widely studied. Its safety profile is very well established, and the drug is well
tolerated in long-term use, even in older patients. There was more evidence for its effectiveness in
stroke than for that of alternatives, such as citalopram.25 A number of manufacturers produce the drug
and the price was low, which makes it particularly attractive to health services that are under severe
cost pressures. Finally, of all the SSRIs, it has the longest half-life; therefore, gradual reduction in dose
is not required when withdrawing the drug (which is inevitable in a trial), which is typically carried out
to avoid the possibility of a SSRI-withdrawal syndrome.26
Potential concerns of using fluoxetine in stroke patients
There are potential risks associated with giving fluoxetine to a wide range of stroke patients. Its reported
interaction with antiplatelet and anticoagulant medication might increase bleeding risk, although this
is usually minor and limited to bruising. Like other antidepressants, fluoxetine may lower the seizure
threshold and, therefore, could increase the frequency of post-stroke seizures. In our Cochrane review,
there was a non-significant excess of seizures in patients who were allocated SSRIs.25 Therefore, we
excluded from the FOCUS trial patients who had a history of epileptic seizures. An adverse effect on
glycaemic control in diabetic patients has been recorded. Hyponatraemia is a recognised adverse effect
and may prove to be more common among stroke patients who may be taking concomitant angiotensin-
converting enzyme (ACE) inhibitors, diuretics and proton pump inhibitors. Observational studies have
suggested that bone fractures are more common in those taking SSRIs, and this has variably been
attributed to an increased risk of fractures in depression, increased risk of falling while taking SSRIs
(possibly owing to drowsiness, increased activity or motor effects) and direct effects of SSRIs on bone
strength.27,28 Furthermore, there are already concerns that stroke patients have a greater risk of falls
owing to their neurological and functional deficits or concurrent medications (e.g. antihypertensive
medication), and greater risk of fractures owing to osteoporosis affecting hemiplegic limbs.29,30
Nevertheless, fluoxetine has been very commonly prescribed for several years for selected patients
who have had a stroke to treat depression and emotionalism without major problems emerging.
Patients who are commenced on psychotropic drugs, including fluoxetine, are encouraged to monitor
the effects on their psychomotor function before resuming driving. However, stroke patients in the
UK are advised not to drive for at least 1 month after a stroke, which should provide ample time
in the trial for any potentially important adverse effects that would affect their driving ability to
become apparent.
Rationale for the study
The need for large randomised trials of fluoxetine in stroke
Given these encouraging data, which suggested that fluoxetine might have substantial benefits for a
wide range of stroke patients, there was an urgent need to carry out RCTs with adequate power to
reliably detect clinically important benefits. Given that fluoxetine is inexpensive (approximately £2.50
per patient per month in the UK), simple to administer and generally well tolerated, if it had an effect
that was a fraction of that seen in the FLAME trial17 it would be a very worthwhile treatment option
for patients, their carers and health and social services.
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The need to identify the patients who might particularly benefit from treatment
Although fluoxetine might improve outcome for a range of stroke patients, it is also plausible, given
its diverse pharmacological effects, that the balance of risk and benefit may vary in patients who have
had different types of stroke. For instance, pre-clinical work had suggested that motor recovery may
be specifically enhanced. In addition, fluoxetine influences bleeding risk, particularly in those taking
antithrombotic medication, so there could be differences in effectiveness between patients who have
had an ischaemic stroke (who are taking antithrombotics) and patients who have had a haemorrhagic
stroke. Patients who have had a severe stroke associated with cognitive and communication problems
may be at greater risk of adverse effects because they are unable to report early problems, but they
might also have more to gain from a treatment that enhances recovery. In addition, patients who have
had a severe stroke are normally at greater risk of post-stroke depression (which may be associated
with stroke severity); however, as a consequence of their deficits, these patients are at greater risk
that their post-stroke depression is not recognised and, thus, not treated.
The FOCUS trial collaboration (see Appendix 1 for membership) aimed to robustly address several
research questions.
Primary research question:
1. Does the routine early administration of fluoxetine [20 mg once per day (o.d.)] for 6 months after an
acute stroke improve patients’ functional outcome?
Secondary research questions:
2. If fluoxetine improves functional outcome, does any functional improvement persist after treatment
is stopped?
3. Among patients who have had an acute stroke –
i. If there is motor impairment, does fluoxetine improve patients’ motor function and does any
improvement persist after treatment is stopped?
ii. If there is communication impairment, does fluoxetine improve patients’ communication function
and does any improvement persist after treatment is stopped?
iii. If there are impairments that preclude the formal assessment of post-stroke mood, does
fluoxetine improve patients’ functional outcomes?
iv. Does fluoxetine improve patients’ outcome with respect to mood, fatigue, cognition, health-
related quality of life (HRQoL) or participation and does any improvement persist after treatment
is stopped?
v. Does fluoxetine reduce the cost of health care over the first year?
vi. Does fluoxetine increase the risk of serious adverse events?
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Chapter 2 Methods
The full trial protocol is available at www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#.
Design overview
The FOCUS trial was a pragmatic, investigator-led, multicentre, parallel-group, double-blind, placebo-
controlled trial with broad entry criteria and follow-up to ascertain the primary and secondary
outcomes at 6 and 12 months.
Setting
The FOCUS trial was carried out in hospital-based stroke services in the UK.
Participant inclusion/exclusion criteria
Inclusion criteria
l Aged ≥ 18 years.
l Brain imaging was compatible with intracerebral haemorrhage or ischaemic stroke.
l Randomisation could be undertaken between 2 and 15 days after stroke onset.
l Persisting focal neurological deficit was present at the time of randomisation. This needed to be
severe enough to warrant 6 months’ treatment with the FOCUS trial medication from the patient’s
or carer’s perspective.
Exclusion criteria
l Subarachnoid haemorrhage (except where secondary to a primary intracerebral haemorrhage).
l Unlikely to be available for follow-up for the next 12 months (e.g. had no fixed home address).
l Unable to speak English and had no close family member available to help with follow-up forms.
l Other life-threatening illness (e.g. advanced cancer) that would have made 12-month
survival unlikely.
l History of epileptic seizures.
l History of allergy to fluoxetine.
l Contraindications to fluoxetine, including:
¢ hepatic impairment (alanine aminotransferase level more than 3 times the upper normal limit).
¢ renal impairment (creatinine level of > 180 µmol/l).
l Pregnancy or breastfeeding, and women of childbearing age not taking contraception. Minimum
contraception was an oral contraceptive.
l Previous drug overdose or attempted suicide.
l Already enrolled into a clinical trial of an investigational medicinal product (IMP).
l Current or recent (within the previous month) depression requiring treatment with a
SSRI antidepressant.
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5
l Current medications that have a serious interaction with fluoxetine, including:
¢ Use of a monoamine oxidase inhibitor during the previous 5 weeks [e.g. phenelzine (Nardil®,
Kyowa Kirin Ltd, Tokyo, Japan), isocarboxacid, tranylcypromine, moclobemide (Manerix®, Mylan,
Canonsburg, PA, USA), selegiline (Eldepryl®, Orion Pharma UK, Newbury, UK) and rasagiline
(Azilect®, Teva UK Ltd, Castleford, UK)].
¢ Pimozide (Orap®, Eumedica Pharmaceuticals, Basel, Switzerland).
¢ Metoprolol for heart failure [introduced late in 2016 after a change to the summary of product
characteristics (SmPC)] (see Report Supplementary Material 1).
Consent
The investigator was responsible for ensuring that informed consent was obtained and the consent form
was completed, signed and dated by all parties before any protocol-specific procedures were carried out.
Participant information booklets (PIBs) and informed consent forms (ICFs) were provided (see the project
web page: www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#; accessed 7 May 2020). Separate
versions were available for patients with capacity; proxies were used for patients without capacity. We
developed easy-access versions for patients or proxies with cognitive or communication difficulties
(see Appendix 2). The verbal explanation to the participant was provided by the investigator or designated
person, and aimed to cover all the elements specified in the PIB/ICF. The participants were given every
opportunity to clarify any points that they did not understand and, if necessary, ask for more information.
Participants could withdraw their consent to participate at any time without loss of benefits to which they
would otherwise be entitled.
The participants consented to their medical records being inspected by regulatory authorities and
representatives of the sponsor(s) and agreed that the information held and maintained by NHS Digital
and other central UK NHS bodies could be shared with us and may be used to help contact them or
provide information about their health status.
Written informed consent from the patient was always sought where possible. If this was not possible
because the patient could not write, the randomising clinician or nurse could gain witnessed verbal
consent. Laws governing consent procedures, and in particular those governing incapacitated adults
and their involvement in research, were followed.
The patient or personal legal representative received a folder including a copy of the relevant version
of the PIB, a copy of the completed ICF and a patient diary that contained contact details for the
trial co-ordinating centre and prompted the recording and reporting of safety outcomes and adverse
events, etc. The original ICF and PIB were filed in the site file with the randomisation form (see the
project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#; accessed 7 May 2020).
The completed ICF was also scanned and uploaded onto the secure trial website or e-mailed, or faxed,
to the trial office, before randomisation. The trial management system prompted the research team to
do so via e-mail and/or fax until the consent form had been received.
Randomisation
Having obtained consent, the randomising person collected the baseline data necessary to complete
a randomisation form (see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/
130430/#; accessed 7 May 2020) and entered the patient’s baseline data into our computerised central
randomisation service by means of a secure 24 hours per day/7 days per week (24/7) web interface.
After the computer program checked these baseline data for completeness and consistency, it allocated
that patient a unique study identification number and a treatment pack number that corresponded to
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either fluoxetine or placebo. The system applied a minimisation program to achieve balance between the
treatment groups for four factors:
1. delay since stroke onset (2–8 vs. 9–15 days)
2. predicted 6-month outcome (based on the six simple variable model)31
3. presence of a motor deficit (based on NIHSS)13
4. presence of aphasia (based on NIHSS).
The six simple variable model is a statistical model that predicts survival and functional outcome after
stroke.31 The variables are (1) the patient’s age, (2) whether or not the patient was independent prior
to the stroke, (3) whether or not they lived alone, (4) whether or not after the stroke the patient could
lift both arms off the bed, (5) walking without help of another person and (6) talking without being
confused (i.e. normal on the verbal component of the Glasgow Coma Scale32).
The minimisation algorithm randomly allocated the first patient to a treatment, but allocated each
subsequent patient to the treatment that minimised the imbalance between the treatment groups
with respect to the prognostic factors.33 It was designed to allocate equal numbers to each of the
two treatment groups (i.e. a 1 : 1 ratio). To ensure that we retained a random element to treatment
allocation, patients were allocated to the group that minimised differences between groups with a
probability of 0.8. The system contained a list of treatment codes for each centre and that matched
the stocks held at that centre. At the end of the session, each patient was allocated a treatment code
that corresponded to an active (20 mg of fluoxetine o.d.) or placebo treatment pack that contained a
6-month supply of capsules held at that centre.
The randomisation system took account of the drug stocks that were held locally to (1) ensure that the
allocated treatment was available and (2) minimise wastage. The randomisation system automatically
generated an e-mail/fax to the centre co-ordinator and the local research pharmacist to ensure that the
allocated treatment was prescribed. The pharmacist or co-ordinator could access treatment codes to replace
lost study medication through a secure website by entering the patient’s study ID number and date of birth.
To facilitate drug reconciliation and stock control, the pharmacist or local co-ordinator removed an
adhesive treatment number label (flag) from the medication bottle, stuck it onto the confirmation of
allocation fax and faxed it back to the trial co-ordinating centre. The trial management system
prompted them to do so via e-mail and/or fax until the fax was received.
Following randomisation, the trial co-ordinating centre sent a letter to inform the general practitioner
(GP) of the patient’s enrolment in the trial, including a copy of the consent form and the follow-up
schedule (see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#;
accessed 7 May 2020).
The interventions
The interventions were 20 mg of fluoxetine o.d. or placebo for 6 months. The study medication (active
and placebo) was manufactured by Unichem (Mumbai, India), imported by Niche Generics Ltd (Hitchin,
UK), purchased from Discovery Pharmaceuticals Ltd (Castle Donington, UK) and quality assured,
packaged, labelled and distributed by Sharp Clinical Services (Tredegar, UK). Patients were supplied
with 186 capsules and were prescribed the study medication (20-mg capsules of fluoxetine or placebo)
to be taken daily. If the patient was unable to swallow capsules and had an enteral feeding tube in
place, the capsules were broken open and the contents put down the tube.
We measured adherence to the study medication in several ways: recording the date of first and last
dose taken, number of missed doses while in hospital, capsule counts when unused capsules were
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returned and estimated adherence at 6-month follow-up. We recorded the reasons for stopping the
study medication early. Our primary measure of adherence was the best estimate of the interval
between the first and the last dose based on all of the information available. Therefore, for a particular
participant, a capsule count might lead us to modify the estimate of the timing of the last dose (see
Chapter 3 for more detail).
Blinding
The patient, their families, the health-care team including the pharmacist, the staff in the co-ordinating
centre and anyone involved in outcome assessments were blinded to the treatment allocation by using
a placebo capsule that was visually identical to the fluoxetine capsules, even when broken open to
allow the administration of the trial medication down an enteral feeding tube.
An emergency unblinding system was available. If a clinician thought that they needed to know the
allocated treatment for a patient, they were asked to telephone a 24/7 helpline that was manned
by staff from a co-ordinating centre, and provided access, directly or indirectly, to one of our chief
investigators. The case for unblinding was discussed and, if agreed, the clinician was given a unique
code (based on a simple arithmetic manipulation of the date) to unlock the web-based unblinding
system. The clinician could then enter the patient’s details, along with the reason(s) for unblinding,
and they were provided with the treatment allocation. This was designed so that those in the
co-ordinating centre and those conducting follow-up remained blind to the treatment allocation.
Our information technology system logged any attempts to unblind.
Primary outcome
The primary outcome was the mRS (based on ordinal analysis to maximise power and to avoid
the problem of including patients with a mRS of > 2 prior to their stroke) at 6 months after
randomisation.18,34 We also collected data on mRS at 12 months (one of our secondary objectives).
Patients who died were attributed a score of 6 for this analysis.
The mRS is a simple, time-efficient measure with well-studied reliability that is used to categorise levels
of functional outcome (see Table 10). It has been used extensively in large, multicentre stroke trials.
Any misclassification of patients into an inappropriate mRS category may reduce the power of the trial.
To minimise misclassification and intermodality differences, we used the simplified modified Rankin
Scale questionnaire (smRSq) described by Bruno et al.18,35,36 This can be delivered via telephone and
postal questionnaires and has been completed by patients and proxies.36,37
Secondary outcomes
To answer our secondary objectives, we collected the following outcome measures:
l Deaths from all causes by 6 and 12 months.
l The EuroQol-5 Dimensions, five-level version (EQ-5D-5L) to provide an overall measure of HRQoL
and to allow a health economic analysis based on quality-adjusted life-years (QALYs).38
l The Mental Health Inventory – 5 questions (MHI-5), which is derived from the Short Form
questionnaire-36 items (SF-36) and provided a measure of depression and anxiety symptoms.
This brief measure performs well, compared with longer questionnaires (e.g. Mental Health
Inventory – 18 questions, General Health Questionnaire –12 questions and General Health
Questionnaire –30 questions), in the detection of depression and anxiety symptoms.39–41
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l The vitality subscale of the SF-36 was used to assess patients’ levels of fatigue.42,43
l The Stroke Impact Scale (SIS) provided an overall assessment of patient outcome as well as allowing
us to assess the effect of treatment on specific outcomes of importance to the patients. The SIS is a
stroke-specific, comprehensive health status measure. The scale was developed with input from
patients and caregivers and comprises eight domains (strength, hand function, activities of daily
living/instrumental activities of daily living, mobility, communication, emotion, memory and thinking,
and participation) from across the full impairment–participation continuum.44–46 It also provided an
overall assessment of recovery with a visual analogue scale. The scale has been validated for use by
proxy respondents and has been delivered via telephone and postal questionnaires.45,47,48
Safety outcomes
l New diagnosis of depression since randomisation. This was collected at 6- and 12-month follow-up
with GPs and participants. We recorded who had made the diagnosis, whether or not any treatment,
and specifically any treatment with antidepressant medication, was initiated and whether or not
there was any attempt at suicide or self-harm. Sometimes patients were started on an antidepressant
without a clear prior diagnosis; in these cases, we made an individual judgement based on all available
information and whether the antidepressant had been started for new depression (or low mood) or
for another indication, such as neuropathic pain, anxiety or emotionalism without depression.
l Other adverse events, including further strokes (ischaemic or haemorrhagic), acute coronary events,
upper gastrointestinal haemorrhage, falls resulting in injury, new bone fractures, epileptic seizures,
symptomatic hypoglycaemia (< 3 mmol/l), hyperglycaemia (> 22mmol/l) and hyponatraemia
(Na+ < 125mmol/l). Retrospectively, we also categorised patients with other serious bleeds (e.g. lower
gastrointestinal, renal tract and subdural) and thrombotic events (deep-vein thrombosis, pulmonary
embolism, mesenteric thrombosis, ischaemic limbs) that led to hospital admission. Information on
these events were collected via centres, GPs and participants at discharge and 6 months, although
we became aware of some events occurring later because they led to hospital admissions that we
recorded at the 12-month follow-up.
Follow-up
The principal investigator (PI) and researchers at each site collected the local data listed in the
schedule of study assessments below. The chief investigators and the research team in the central
co-ordinating office collected the central data (Table 1).
TABLE 1 Study assessment schedule
Assessment
Days Weeks
2–15 4–6 12 24 26 30 50 52 54
Local
Screen of eligibility ✓
Check results of post-stroke bloods ✓
Give PIB to patient and/or carer ✓
Consent ✓
Collect baseline data ✓
Randomise ✓
continued
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TABLE 1 Study assessment schedule (continued )
Assessment
Days Weeks
2–15 4–6 12 24 26 30 50 52 54
Record treatment code/study number ✓
Prescribe study medication ✓
Dispense 6 months’ worth of treatment ✓
Fax treatment code ✓
Complete discharge form, including: +
Adverse events +
All medications +
Adherence +
Updated contact details +
Central (postal or telephone)
E-mail/fax notification of allocation ✓
Letter informing GP of participation ✓
1-month follow-up for outpatients o
Send fax alert following discharge to GP of
patient participation
✓
Courtesy call to participant ✓
3-month prompt to patients ✓
GP questionnaire ✓
New depression ✓ ✓
Other adverse events o ✓
Follow-up on previous adverse events ✓ ✓
All medications o ✓ ✓
Adherence o ✓
Resource use ✓ ✓
Patient follow-up
Safety outcomes and adverse events o ✓
Follow-up on previous adverse events ✓ ✓
Adherence o ✓
mRS ✓ ✓
SIS ✓ ✓
MHI-5 ✓ ✓
EQ-5D-5L (HRQoL) ✓ ✓
SF-36 vitality subscale ✓ ✓
Resource use ✓ ✓
Retrieve residual capsules (pill count,
reconciliation and destruction)
✓
+, Only for patients enrolled as inpatients; o, only for patients enrolled as outpatients.
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Study safety assessments
Our monitoring system was primarily aimed at identifying suspected unexpected serious adverse
reactions (SUSARs), but also at identifying whether or not the frequency of serious adverse reactions
was greater than in other populations given fluoxetine and sufficiently common to offset any benefits.
We did not aim to detect the occurrence of the very many adverse events that occur in stroke patients
and that were very unlikely to be related to participation in the trial or the medication.
The trial materials given to the patient and/or their carer contained details of the known adverse
reactions to fluoxetine (based on the SmPC) and the adverse events that commonly occur after
stroke. They received a diary in which they were encouraged to record the date and nature of any
adverse events.
Patients who were enrolled while they were an inpatient had a hospital discharge form completed by
the local co-ordinator at the time of discharge from the recruiting centre or shortly after. The data
collected were entered on a secure web-based form or faxed to the co-ordinating centre to ensure
that we were alerted to any important adverse reactions. We regularly prompted centres to complete
discharge forms for patients with incomplete data.
Patients who were enrolled while they were an outpatient had a central follow-up at 1 month after
recruitment to detect safety outcomes and adverse reactions.
At 12 weeks after randomisation, the trial co-ordinating centre staff posted a reminder to the patients
to report any adverse events or difficulties with the trial medication, but this was not followed up
unless a response was received.
All surviving patients who had not withdrawn consent or indicated that they did not want to be
contacted directly were followed up at 6 and 12 months after randomisation, whether or not they
adhered to their allocated treatment. At each follow-up, the GP was asked about safety outcomes and
other adverse events. In order to detect adverse reactions between the scheduled follow-ups, patients,
their carers or their GPs could report any adverse reactions to us via:
l post – a Freepost envelope and adverse events form to return to us with details of any adverse
reactions that the patient had experienced
l a helpline – a telephone number that allowed the patients or their doctors to leave a message
(if non-urgent) or to access a trial doctor (if urgent).
About 2 weeks before any central follow-up was due, the trial co-ordinating centre staff contacted the
GPs (or hospital co-ordinators if no discharge form had been received) to check that the patient was
alive and that they may be approached for follow-up. The GP was asked (and paid a fee of £56.00)
to provide a list of non-IMPs and to complete a questionnaire including information regarding the
patient’s adherence to the IMP, details of any safety outcomes or adverse events, hospital admissions
and up-to-date contact details for the patient.
If appropriate, the trial co-ordinating centre then posted a questionnaire to the patient at 4 weeks
(only for those recruited as outpatients), 26 weeks and 52 weeks. If the patient did not respond to the
postal questionnaire, they were telephoned by the co-chief investigators at 6 months and by a trained
member of the team at 12 months. The questionnaire at 26 and 52 weeks aimed to capture the
primary and secondary outcomes and included the outcome of any adverse events that have been
reported earlier in the follow-up. If the patient had incapacity, the next of kin (proxy) was asked to
complete and return the forms. If the patient was unable to speak English, we asked that their carer
supported them in filling out the forms. If the follow-up information could not be obtained by the
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postal or telephone questionnaire, we asked the local research team to arrange a face-to-face follow-up at
a clinic or home visit.
Data linkage and extract to determine outcome and long-term survival
We collected data from our participating hospitals, the patients and their GPs about hospital
admissions during the first 12 months. However, we also planned to obtain information about the
health status and resource use of participants to determine outcomes beyond the end of the trial from
the Health and Social Care Information Centre. This function has been devolved to NHS Digital in
England and Wales and the eData Research and Innovation Service (eDRIS) in Scotland. No centrally
held data are available for Northern Ireland.
Management of depression in the trial
Our hypothesis was that new episodes of depression would be less commonly diagnosed and treated in
the group allocated to fluoxetine. We ascertained cases of depression by:
l asking about a diagnosis or initiation of an antidepressant during hospital admission or during the
first month – this was recorded on the locally completed discharge form or the 1-month central
follow-up form
l asking the GP at 6 months and 12 months
l asking the patient (or their proxy) at 6 months and 12 months.
Because the primary question addressed by the FOCUS trial was whether or not a SSRI (20 mg of
fluoxetine o.d.) enhanced recovery from stroke, it would be an advantage if the control group were
kept free from any SSRIs, including fluoxetine. However, it would be unethical to deny patients in the
trial access to effective antidepressant treatment. We therefore asked collaborating clinicians and the
patients’ GPs to adhere to the following treatment guideline.
If a patient in the FOCUS trial was diagnosed as having depression (or pathological emotionalism) that
the responsible clinician judged to be severe enough to justify treatment with antidepressant drugs,
we recommended that, if possible, they should avoid any SSRIs and prescribe either mirtazapine or
trazodone. Both drugs are compatible with fluoxetine (there are no common or important interactions),
although because mirtazapine has some serotonergic activity there is likely to be a slightly greater risk
of precipitating a serotonergic syndrome. Both drugs were recommended by the National Institute for
Health and Care Excellence (NICE) for treatment of depression in patients with physical illness.26 The
clinician might alternatively use a tricyclic antidepressant of their choice. We advised that patients
taking the trial drug and another antidepressant should be monitored carefully (e.g. check plasma
sodium levels to exclude hyponatraemia) to identify any potential interactions.
Sample size
We planned to enrol at least 3000 patients in the main phase of the FOCUS trial. This aimed to
provide 90% power with a two-sided 5% level of significance to detect a 5.6% absolute increase in
percentage with mRS 0–2 from 27.0% to 32.6% based on an ordinal analysis, which is statistically more
efficient than an analysis that dichotomises the mRS.34
In arriving at this sample size, we took account of the effect sizes seen in the FLAME trial17 alongside
the effects that we judged clinicians and their patients would find interesting. Because fluoxetine is
safe and inexpensive, the FOCUS trial sought to reliably detect a moderate, but nonetheless clinically
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important, benefit that might be associated with widespread use of fluoxetine in this population.
However, we also took account of the feasibility of enrolling large numbers of patients into the
FOCUS trial.
We based our expected outcomes for our placebo group on the distribution of the mRS score
measured at 6 months after randomisation in the CLOTS trials,49,50 which evaluated graduated
compression stockings.
We used the ordered categorical data method described by Machin et al.51
The Trial Steering Committee (TSC) reviewed the target sample size and could adjust this based on:
l advice from the Data Monitoring Committee (DMC)
l accruing data on –
¢ the enrolment into specific prespecified subgroups
¢ completeness of follow-up
¢ distribution of mRS categories in the population of enrolled subjects (i.e. both treatment groups
combined), overall and in specific patient categories (e.g. those with motor deficits or aphasia).
For example, if the distribution of mRS was different from that anticipated, then the sample size could
be increased. This approach had the advantage that such sample size adjustments could be made
without reference to the accumulating unblinded data, and avoided the need for conditional power
calculations, which could be unreliable.
Statistical analyses
Our statistical analysis plan was published prior to completion of data collection.52 We summarise
the plan here but, rather than reproduce the whole plan in detail, we have indicated in Chapters 3–7
which analyses were not specified in the published plan. For all analyses, unless otherwise specified,
we retained participants in the treatment group to which they were originally assigned, irrespective of
the treatment they actually received (i.e. an intention-to-treat analysis). A statistical significance level
of p < 0.05 (two tailed) was applied to all analyses. The final prespecified analyses were performed on
the data set after any ‘cleaning’ that was required had been completed and the database was locked.
The treatment allocation was only then unblinded. Certain post hoc analyses presented in this report
included data that had been further cleaned after the main analyses had been carried out and
published to correct minor anomalies detected during the analyses.
Primary analysis
This aimed to address our primary research question: does the routine early administration of
fluoxetine (20 mg o.d.) for 6 months after an acute stroke improve patients’ functional status at
6 months? To minimise missing data, our analyses of the primary outcome included a mRS score
obtained between 90 days and 1 year after randomisation, taking the value measured closest to the
6-month time point.
The primary analysis used an ordinal logistic regression adjusted for factors in the baseline
minimisation but also reported in an unadjusted manner. This approach is recommended by the
Medicines and Healthcare products Regulatory Agency (UK). The ordinal analysis of mRS was
conducted by treatment allocation, under the assumption of proportional odds in the model.
This assumption was tested using the score test for proportional odds assumption.
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
13
All of the analyses were programmed by our trial statistician (CG), but the primary analysis was also
independently programmed by a second statistician and the results were compared; any inconsistencies
were identified and resolved by discussion.
Secondary analyses
Analyses of secondary outcomes and analysis of our primary outcome (ordinal mRS) in predefined
subgroups were carried out to address the other research questions. Where the outcome of interest
was binary, comparison by treatment group was examined using a binary logistic regression and
adjusted for factors used in the minimisation algorithm.
Where the outcome of interest was continuous, descriptive statistics are presented [n, mean, standard
deviation (SD), minimum, maximum, median, Q1, Q3] and were categorised by allocated treatment.
Owing to the nature of the distribution of these measures in this population, a simple unadjusted
analysis was performed comparing the two treatment groups using a Mann–Whitney U-test (i.e. not
adjusted for variables in the minimisation algorithm).
These analyses were conducted for the following outcomes at 6 and 12 months:
l fatigue measured by the vitality subscale of the SF-36
l individual SIS domain scores, a ‘motor score’ derived from averaging scores across three domains
(arm, hand, leg and foot strength; hand function; and mobility), a ‘physical function score’ derived by
averaging across four domains (arm, hand, leg and foot strength; hand function; mobility; and daily
activities) and recovery based on the visual analogue scale
l quality of life as measured by the EQ-5D-5L.
Our analyses aimed to answer the following questions:
1. If fluoxetine improves functional status (mRS) at 6 months, does any improvement in functional
status persist after treatment is stopped? To answer this question, we used ordinal logistic
regression to compare functional status (mRS scores) at the 12-month follow-up, as for our
primary analysis.
2. Does fluoxetine influence the secondary outcome measures (living circumstances, quality of life,
fatigue, stroke impact and mood) at 6 months and/or 12 months? The binary outcomes are living
at home or with relative versus care home, hospital or long-term care; mRS at 6 months and
12 months (mRS 0–2 vs. mRS 3–6); and new diagnosis of depression corroborated by the GP or
hospital after randomisation by 6 months and 12 months. The continuous outcomes are EQ-5D-5L,
vitality subscale of SF-36, SIS and MHI-5.
3. Does fluoxetine increase the risk of serious adverse events? We compared the proportion of
patients having any of the following adverse events (all binary outcomes) between randomisation
and cessation of the trial medication (i.e. IMP), based on treatment received rather than intention
to treat:
(a) any recurrent stroke
(b) ischaemic stroke [not transient ischaemic attacks (TIAs)]
(c) haemorrhagic stroke
(d) acute coronary syndromes
(e) epileptic seizure
(f) episode of hyponatraemia (Na+ < 125 mmol/l)
(g) upper gastrointestinal bleeding
(h) other major bleeds (lower gastrointestinal, extracranial, urinary or intracranial
but extracerebral)
(i) poorly controlled diabetes including hyperglycaemia (> 22 mmol/l) or
symptomatic hypoglycaemia
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(j) falls resulting in injury
(k) new bone fractures
(l) attempted suicide/self-harm.
4. If fluoxetine is clinically effective, is it also cost-effective? We carried out a within-trial economic
analysis of direct resource costs and health outcomes on an intention-to-treat basis. A health
service perspective was adopted for measuring and valuing health service use over a 12-month
time horizon. The methods are described in Chapter 6.
5. Is fluoxetine associated with longer survival? Functional outcome at 6 months post stroke is
strongly associated with long-term survival; therefore, we wished to determine whether or not
any benefits to functional outcome would translate into longer-term survival.53 We used Cox
proportional hazards regression to analyse the effect of treatment on survival to 12 months.
We adjusted for the variables included in our minimisation algorithm. We present this analysis
graphically [cumulative hazard of death (%) vs. time], providing a hazard ratio (HR) with 95% CIs
and a p-value. This analysis will be repeated if survival data for a more prolonged period become
available and sufficient resources are available to perform and report the analyses.
6. Does the presence or absence of any of the following factors materially alter the effect of
fluoxetine on our primary outcome?
(a) Stroke pathology (ischaemic vs. haemorrhagic vs. uncertain pathological type).
(b) Age (≤ 70 or > 70 years).
(c) Stroke severity [i.e. baseline probability of a good outcome on mRS calculated with the six
simple variable model31 to see if effects remain constant across the range of stroke severities
(≤ 0.15 vs. > 0.15–1)].
(d) Patients who were unable to consent for themselves, as this subgroup will allow us to address
the question of whether or not routine use of fluoxetine is likely to benefit patients in whom a
formal assessment of mood is impossible because of communication and cognitive problems.
(e) Inability to assess mood because of communication or cognitive problems [NIHSS Q1b > 0
or Q1c > 0 or Q9 > 1 or unable to answer Patient Health Questionnaire 2 (PHQ2)54 at
randomisation]. Defining the patients’ ability to have their baseline mood assessed based on
NIHSS and PHQ2 is likely to be more meaningful than based on patient or proxy consent
(see d above), especially because no proxy consent is allowed in Efficacy oF Fluoxetine –
a randomisEd Controlled Trial in Stroke (EFFECTS) (Sweden).
(f) Patients with and without depression at baseline because our systematic review suggested
that the effects of SSRIs were greater in those who were depressed.25 Depression at baseline
was defined as an affirmative response to our baseline question of whether or not the patient
has current depression or to both questions in the PHQ2 at baseline.
(g) The functional status (mRS) at 6 months was compared with ordinal logistic regression in
these mutually exclusive subgroups by entering a treatment-by-subgroup interaction into the
regression model.
7. In patients with motor deficits at randomisation, does fluoxetine improve motor function?
Patients with motor deficits were defined as those with a motor deficit affecting the face/arm
or leg (based on NIHSS Q5–9 of > 0). For this subgroup analysis, in addition to comparing their
overall functional outcome based on the ordinal analysis of mRS, we compared the motor score
with the physical function scores based on the SIS domains described above.
8. In patients with aphasia at randomisation, does fluoxetine improve communication? Patients with
aphasia were defined as those with an NIHSS Q9 of > 0. For this subgroup analysis, in addition to
comparing their overall functional outcome based on mRS based on ordinal analysis, we compared
with the SIS communication subscale.
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9. For questions 7 and 8, because patients may have a combination of neurological deficits, individual
patients may appear in more than one subgroup.
10. Is there a relationship between functional status at 6 months and mood and is this relationship
affected by fluoxetine? We performed exploratory analyses of potential mediating factors (e.g. the
role of depression).
Missing data
Our randomisation systems did not allow investigators to proceed to treatment allocation without
entering complete baseline data. The mRS, our primary outcome, includes death; therefore, the number
of participants with missing mRS at follow-up was small. Anyone with a missing mRS was not included
in any analysis requiring mRS (complete-case analysis).
For secondary outcomes [e.g. SIS, MHI-5, vitality subscale of the SF-36 and EQ-5D-5L] for which
missing data were expected because data were not available for patients who did not survive, we
presented results for those who were alive at follow-up and any discrepancies in death rates between
groups were taken into account in the interpretation. Missing data for single questions within scores
were handled as detailed by each scoring method. Where responses to all questions within a scale or
subscale were missing, that patient was not included in that part of the analysis.
Protocol deviations, adherence and blinding
Inclusion/exclusion violations: we reported the number and percentage of participants randomised who
did not meet the entry criteria (e.g. non-strokes), with exclusion criteria. However, they were included
in the primary analysis. A secondary analysis excluded ineligible patients (see below).
Unblinding: we reported the number of patients who required unbinding of study medication during
the trial by treatment group and, where available, present the reasons for unblinding.
Adherence: each participant was issued with a 6-month supply of trial medication (186 capsules).
At 6 months, they were asked if they had completed the course and taken all of the capsules and how
often they took capsules on average. They were asked the reasons for stopping, as well as the date of
stopping. Where possible, we retrieved and counted the unused trial medication. Before unblinding,
we derived an estimated date on which the patient was thought to have taken their last dose of trial
medication and used the interval (days) from first dose to that date as our main measure of adherence.
This was based on all of the available information. We used a combination of the following to define
several types of non-adherence to the protocol (see 1–8 below):
l inclusion/exclusion violations
l the answers to the adherence questions (see above)
l number, percentage and duration of any open-label SSRI intake before the 6-month follow-up
l the reasons for stopping trial medication.
A so-called intention-to-treat analysis, in which patients’ outcomes are analysed in the groups that
they were randomised to regardless of treatment received, provides the least biased and most robust
evidence of the effect of treatment. However, the observed treatment effect may be reduced if a large
number of patients are included who are unlikely to benefit because they did not have a stroke or
more likely where a large proportion of patients do not receive the allocated treatment or actually
received the alternative treatment (i.e. cross-overs).
METHODS
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Where the primary analysis does not demonstrate an improvement of functional outcome (mRS) at
the 6-month follow-up, the question arises of whether or not this is this likely to be a result of poor
adherence to the protocol and/or trial medication? This is important because we would not wish to
abandon a potentially useful treatment simply because of poor adherence to trial protocols or trial
medication. These might be improved in any future trials. We undertook further per-protocol analyses
to reassure the clinical community that the trials have not underestimated any treatment effect to an
extent that would alter future clinical practice, or more likely the need for further randomised trials of
SSRI in stroke.
Inevitably, analyses that try to take account of adherence introduce a degree of patient selection and,
thus, are likely to introduce bias.
These prespecified exploratory sensitivity analyses to account for non-adherence included all of the
analyses of the primary outcome and selected secondary outcomes:
l living at home or with relative versus care home, hospital or long-term hospital care
l mRS at 6 months and 12 months (mRS 0–2 vs. mRS 3–6)
l new diagnosis of depression between randomisation and 6 months and 12 months
l SIS domain scores
l averaged score over all SIS domains
l SF-36 vitality subscale score
l utility based on EQ-5D-5L and population preferences.
These analyses do not include any analysis of subgroups defined on the basis of baseline variables.
The following groups were sequentially added to the group excluded from the analyses:
1. Patients who did not meet the entry criteria for the trial.
2. Patients who did not receive any trial medication.
3. Patients who received < 90 days of trial medication because of failures in trial procedures, for
example failures to transfer trial medication with patients during moves between hospitals, care
homes and home. The 90-day cut-off point was chosen because previous trials have tested this
duration of treatment with apparent benefit.17,25
4. Patients who received < 90 days of trial medication because of patient or relative concerns but not
because of suspected adverse reactions.
5. Patients who received < 90 days of trial medication because they experienced symptoms that were
attributed to the trial medication.
6. Patients who had been allocated to placebo who received a SSRI (fluoxetine or other) within the
first 90 days and the SSRI was not known to have been stopped within 10 days of starting.
7. Patients who had been allocated to fluoxetine who received a SSRI (fluoxetine or other) within the
first 90 days and the SSRI was not known to have been stopped within 10 days of starting.
8. Patients who did not complete at least 150 days of treatment. We chose this cut-off point because
patients sometimes received the questionnaires shortly before 6 months, and some stopped the
trial medication at that point, whereas others finished the 186 capsules. We regarded both as
fully adherent.
Research governance
The trial was co-ordinated by a Project Management Group: Professor Martin Dennis, Professor
Gillian Mead (the joint chief investigators and PIs for two participating sites), Karen Innes (trial
manager) and Catriona Graham (trial statistician).
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
17
Trial co-ordinating centre
The trial co-ordinating centre was responsible for all aspects of the management of the FOCUS trial
and was based at the Centre for Clinical Brain Sciences at the University of Edinburgh. Responsibilities
included regulatory submissions and compliance; financial management; monitoring of sites; training;
patient information and communication; end-point assessment; data collection systems and data
management; IMP management; statistical analysis; reports and publications; and archiving of the trial
master file in accordance with funder and sponsor requirements.
Trial Steering Committee
A TSC was established, including a stroke survivor and a carer, to oversee the conduct and progress of
the trial. The terms of reference of the TSC, the draft template for reporting and the names and
contact details were agreed at its first meeting (see Report Supplementary Material 1).
Data Monitoring Committee
An independent DMC was established to oversee the safety of participants in the trial. During the
period of recruitment into the study, interim analyses of the baseline and follow-up data were supplied,
in strict confidence, to the chairperson of the DMC, along with any other analyses that the committee
requested. In the light of these analyses, the DMC could advise the chairperson of the TSC if, in their
view, the randomised comparisons had provided (1) ‘proof beyond reasonable doubt’ that for all, or some,
the treatment is clearly indicated or clearly contraindicated and (2) evidence that might reasonably be
expected to materially influence future patient management. Appropriate criteria of proof beyond
reasonable doubt were not specified precisely, but the DMC worked on the principle that a difference of
at least three standard errors in an interim analysis of a major outcome event (e.g. death from all causes
or independent survival at 6 months) would be needed to justify halting, or modifying, the study before
the planned completed recruitment. This criterion has the practical advantage that the exact number of
interim analyses would be of little importance, and so no fixed schedule was proposed. Following a
report from the DMC, the TSC decided whether to modify entry to the study (or seek extra data).
The terms of reference of the DMC, the DMC charter and the names and contact details were agreed
at the first meeting of the DMC (see Report Supplementary Material 2).
Patient and public involvement
In December 2010, service users overseeing a study of post-stroke fatigue commented on our plans
for the FOCUS trial. We met with the group in May 2011. We included their suggestions about patient
information booklets (i.e. explaining the rationale for using fluoxetine in people without depression,
listing all side effects), and agreed that all trial participants would be sent a summary of the trial
results if they wished. A group of stroke survivors with aphasia developed the easy-access version of
the patient information booklet, guided by Professor Marian Brady (see Appendix 2). A stroke survivor,
Judith Williamson, from the National Institute for Health Research (NIHR) Stroke Research Network
(SRN), and Zena Jones (manager of the NIHR SRN patient and public involvement group) attended our
first investigator meeting (in June 2011). In March 2013, the SRN patient and public involvement
group advised us how to enhance the proportion of eligible patients consenting, and how to facilitate
follow-up. This advice featured in our Autumn 2013 newsletter to sites. In November 2013, Ms Jones
and Ms Williamson endorsed our plans to telephone patients immediately after hospital discharge.
They edited the script that would guide the telephone call. They commented on a draft of the funding
application to NIHR. Ms Williamson and a carer were on our TSC, offering advice and comments
METHODS
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throughout the trial. They were particularly influential in discussion of how we would disseminate the
results of the trial to participants and their families. They commented on the final newsletter, which
was sent out on the day the results were presented at conference, and published in The Lancet.55 They
have also had input into the drafting of this report, specifically the Plain English summary.
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Chapter 3 Results 1: conduct
The main results of the FOCUS trial have been published.55 In this chapter, and following chapters,we present the main results and additional information.
Recruitment
Between 10 September 2012 and 31 March 2017, 103 UK hospitals consented 3152 patients and
enrolled 3127 patients. Recruitment was stopped after we had exceeded our minimum target of 3000
patients to account for recruitment of ineligible patients and withdrawals (Figure 1).
The network of centres was built on the networks that we had established to carry out previous trials,
including the CLOTS49,50 and IST343 trials. We enrolled new centres throughout the trial period. The trial
co-ordinating centre worked closely with the research teams at prospective centres, and the majority of
site initiation visits were carried out remotely using telephone and video conferencing. The trial was
facilitated by the NIHR-funded research networks, which provided funding for local research nurses.
Centres also received a £300 pharmacy start-up fee, and approximately £46 per patient recruited.
Thirty-one patients were identified as ineligible between obtaining consent and randomisation; in
other cases, the patients, their proxy or their treating clinician changed their mind about participation
in the trial. Of the 3127 patients who were enrolled, 1564 were allocated to the fluoxetine group and
1563 were allocated to the placebo group. Eleven of these patients did not meet our eligibility criteria:
two in each group had a final diagnosis other than stroke and seven others were identified as meeting
exclusion criteria after randomisation (e.g. a history of epilepsy, self-harm or some other contraindication
to fluoxetine). The ineligible patients were retained in our intention-to-treat analyses. The patients’
progress through the trial is shown in Figure 2.
Randomisation date
July
2012
January
2013
January
2014
January
2015
January
2016
January
2017
Planned recruitment
Actual recruitment
July 
2013
July 
2014
July 
2015
July 
2016
July
2017
N
u
m
b
er
 o
f p
at
ie
n
ts
3000
2000
1000
0
FIGURE 1 Recruitment graph showing planned vs. actual recruitment.
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Baseline characteristics of recruited patients
The baseline characteristics of the two treatment groups were well balanced with respect to all
measured variables (Tables 2–6).55
Patients consented
(n = 3152)
Randomly assigned
(n = 3127)
Assigned to f luoxetine groupa
(n = 1564)
Assigned to placebo groupb
(n = 1563)
Did not submit 6-month form
(n = 140)
Submitted 6-month form 
(n = 1424)
Had mRS data available 
(n = 1553)
Submitted 6-month form 
(n = 1423)
Had mRS data available 
(n = 1553)
Not enrolled
(n = 25)
• Ineligible, n = 15
• Impractical to randomise, n = 2
• Patient changed mind, n = 1
• Doctors changed mind, n = 6
• Unknown, n = 1
• Died, n = 129
• Withdrew consent, n = 10
• Too early (<90 days), n = 1
Did not submit 6-month form
(n = 140)
• Died, n = 130
• Withdrew consent, n = 7
• Too late (<186 days), n = 3
Did not submit 12-month form
(n = 68)
• Died, n = 53
• Withdrew consent, n = 10
• Did not complete 12-month
    form, n = 5
Submitted 12-month form   
(n = 1357)
Had mRS data available 
(n = 1539)
Had vital status known 
(n = 1544)
Submitted 12-month form 
(n = 1346)
Had mRS data available 
(n = 1544)
Had vital status known 
(n = 1552)
Did not submit 12-month form
(n = 80)
• Died, n = 68
• Withdrew consent, n = 4
• Did not complete 12-month
    form, n = 8
FIGURE 2 Participant flow. a, 1544 inpatients with discharge form; 20 recruited as outpatients; b, 1536 inpatients with
discharge form; 27 recruited as outpatients. Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s).
Published by Elsevier Ltd. This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY-NC-ND 4.0) license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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TABLE 2 Baseline characteristics: demographic and social
Characteristics of patients randomised
Allocated treatment
Fluoxetine (N= 1564) Placebo (N= 1563)
Sex, n (%)
Female 589 (37.66) 616 (39.41)
Male 975 (62.34) 947 (60.59)
Age, n (%)
≤ 70 years 666 (42.58) 664 (42.48)
> 70 years 898 (57.42) 899 (57.52)
Age (years), mean (SD) 71.24 (12.35) 71.48 (12.06)
Ethnicity, n (%)
Asian 30 (1.92) 31 (1.98)
Black 35 (2.24) 29 (1.86)
Chinese 0 (0.00) 1 (0.06)
Other 4 (0.26) 9 (0.58)
White 1495 (95.59) 1493 (95.52)
Marital status, n (%)
Married 879 (56.20) 846 (54.13)
Partner 93 (5.95) 91 (5.82)
Divorced/separated 109 (6.97) 100 (6.40)
Widowed 337 (21.55) 354 (22.65)
Single 124 (7.93) 150 (9.60)
Other 22 (1.41) 22 (1.41)
Living arrangement, n (%)
Living with someone else 1057 (67.58) 1034 (66.15)
Living alone 485 (31.01) 516 (33.01)
Living in an institution 10 (0.64) 4 (0.26)
Other living arrangement 12 (0.77) 9 (0.58)
Employment, n (%)
Full-time employment 287 (18.35) 258 (16.51)
Part-time employment 76 (4.86) 70 (4.48)
Retired 1122 (71.74) 1134 (72.55)
Unemployed/disabled 53 (3.39) 60 (3.84)
Other employment 26 (1.66) 41 (2.62)
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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TABLE 3 Baseline characteristics: medical history
Characteristics of patients randomised
Allocated treatment, n (%)
Fluoxetine (N= 1564) Placebo (N= 1563)
Coronary heart disease 281 (17.97) 300 (19.19)
Ischaemic stroke/TIA 274 (17.52) 294 (18.81)
Diabetes 337 (21.55) 303 (19.39)
Hyponatraemia 19 (1.21) 26 (1.66)
Intracranial bleed 27 (1.73) 23 (1.47)
Upper gastrointestinal bleed 25 (1.60) 26 (1.66)
Bone fractures 241 (15.41) 256 (16.38)
Depression 130 (8.31) 123 (7.87)
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 4 Baseline characteristics: stroke diagnosis and classifications
Characteristics of patients randomised
Allocated treatment, n (%)
Fluoxetine (N= 1564) Placebo (N= 1563)
Stroke diagnosis
Non-stroke (final diagnosis) 2 (0.13) 2 (0.13)
Ischaemic stroke 1410 (90.15) 1406 (89.96)
Intracerebral haemorrhage 154 (9.85) 157 (10.04)
OCSP classification of ischaemic strokes
Total anterior circulation infarct 318 (20.33) 317 (20.28)
Partial anterior circulation infarct 561 (35.87) 553 (35.38)
Lacunar infarct 307 (19.63) 283 (18.11)
Posterior circulation infarct 191 (12.21) 230 (14.72)
Uncertain 33 (2.11) 23 (1.47)
Cause of stroke: modified TOAST classification
Large artery disease 278 (17.77) 234 (14.97)
Small vessel disease 252 (16.11) 218 (13.95)
Embolism from heart 377 (24.10) 411 (26.30)
Another cause 38 (2.43) 35 (2.24)
Unknown/uncertain 465 (29.73) 508 (32.50)
OCSP, Oxfordshire Community Stroke Project;56 TOAST, Trial of Org 10172 in Acute Stroke Treatment.57
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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TABLE 5 Baseline characteristics: stroke severity, prognostic variables and mood at baseline
Characteristics of patients randomised
Allocated treatment
Fluoxetine (N= 1564) Placebo (N= 1563)
SSV
Age (years), mean (SD) 71.24 (12.35) 71.48 (12.06)
Independent before stroke, n (%) 1431 (91.50) 1435 (91.81)
Living alone, n (%) 485 (31.01) 516 (33.01)
Able to lift both arms off bed, n (%) 924 (59.08) 935 (59.82)
Able to talk and not confused, n (%) 1166 (74.55) 1164 (74.47)
Able to walk without help from another person, n (%) 435 (27.81) 412 (26.36)
Probability that alive and independent, median (IQR)
(derived from SSV)
0.28 (0.07–0.63) 0.26 (0.07–0.63)
0 to ≤ 0.15, n (%) 592 (37.85) 591 (37.81)
> 0.15 to 1, n (%) 972 (62.15) 972 (62.19)
NIHSS, median (IQR) 6 (3–11) 6 (3–11)
Presence of a motor deficit, n (%) 1361 (87.02) 1361 (87.08)
Presence of aphasia, n (%) 457 (29.22) 449 (28.73)
Current diagnosis of depression (patient/proxy reported), n (%) 26 (1.66) 18 (1.15)
Taking a non-SSRI antidepressant, n (%) 65 (4.16) 77 (4.93)
Current mood: PHQ2,54 n (%)
2 yes responses 81 (5.18) 60 (3.84)
1 yes response 136 (8.70) 130 (8.32)
0 yes responses 1347 (86.13) 1373 (87.84)
IQR, interquartile range; NIHSS, National Institute for Health Research Stroke Scale;13 SSV, six simple variable model.31
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 6 Baseline characteristics: timing, location and source of consent
Characteristics of patients randomised
Allocated treatment
Fluoxetine (N= 1564) Placebo (N= 1563)
Delay (days) since stroke onset at randomisation
Delay, mean (SD) 6.93 (3.64) 6.98 (3.64)
2–8, n (%) 1070 (68.41) 1072 (68.59)
9–15, n (%) 494 (31.59) 491 (31.41)
Enrolled as a hospital inpatient (not outpatient clinic), n (%) 1544 (98.72) 1536 (98.27)
Patient consented, n (%) 1136 (72.63) 1118 (71.53)
Proxy consented, n (%) 428 (27.37) 445 (28.47)
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Withdrawal
The term withdrawal is used widely in RCTs but it is important to be precise about what is meant.
In the FOCUS trial, we separately categorised patients into the following groups:
l patients who had stopped their trial medication, but were content to be followed up
l patients who may or may not have stopped their medication but no longer wanted to be contacted
directly for follow-up information, but were content for us to obtain follow-up information from
family, friends, GPs or routine data sources
l patients or their proxies who withdrew consent and wanted the patient and their data to be taken
out of the study from that point on, so that we used data collected up to that point only.
When we were informed that the patients wished to withdraw, we clarified which of the above applied.
Only 31 patients withdrew consent; the timing and treatment allocations are shown in the participant
flow diagram (see Figure 2) and treatment allocations were fairly well balanced.
Discharge forms
A discharge form (see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#)
was completed for all 3040 patients enrolled as inpatients.
The 6- and 12-month follow-ups
We completed the 12-month follow-up in the trial in June 2018. The participant flow diagram (see
Figure 2) shows the completeness of follow-up with respect to our primary outcome and vital status.
Table 7 shows the methods of follow-up to obtain these data. Forty-nine per cent of 6-month follow-up
assessments were obtained by postal questionnaire (see the project web page: www.journalslibrary.nihr.
ac.uk/programmes/hta/130430/#). The remainder required a telephone reminder or were completed
by telephone interview. The telephone follow-ups for participants not returning postal 6-month
TABLE 7 Methods of follow-up
Method of follow-up
Allocated treatment, n (%)
Fluoxetine Placebo
6 months
Completed 6-month postal questionnaire without telephone prompting 693 (48.6) 700 (49.1)
Required prompting or clarification by telephone to complete 6-month questionnaire 312 (21.9) 276 (19.4)
Completed 6-month questionnaire by telephone 420 (29.5) 450 (31.6)
Total completing 6-month questionnaire 1425 (100.0) 1426 (100.0)
12 months
Completed 12-month postal questionnaire without telephone prompting 745 (54.9) 743 (55.2)
Required prompting or clarification by telephone to complete 12-month questionnaire 195 (14.4) 179 (13.4)
Completed 12-month questionnaire by telephone 417 (30.7) 424 (31.5)
Total completing 12-month questionnaire 1357 (100.0) 1346 (100.0)
RESULTS 1: CONDUCT
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questionnaires were carried out by the two co-chief investigators (MD and GM) who were trained
and certified in the use of the mRS and had conducted an independent validation of the smRSq.18,35,36
Those conducting the 12-month telephone follow-ups had received training in their application.
Based on our previous trials, we had expected 80% of follow-up to be returned by postal questionnaire,
rather than 50%. This placed a much greater burden on the central co-ordinating team than expected.
In addition, in the FOCUS trial, patients were followed up at 6 and 12 months, doubling the number of
follow-ups. Because missing outcome data would reduce the power of the trial, and can more importantly
introduce bias because it is rarely missing randomly, the central team allocated far more time and
resources to follow-up than had been planned.
Reasons for the low response rate
We did not formally assess the reasons for the low rate of response to the postal questionnaires,
but the following issues contributed:
l Centres providing incomplete or inaccurate postal addresses for participants. Increasingly, stroke
services admit patients acutely to one hospital and then transfer the patients to another hospital,
or community rehabilitation centre, for ongoing care. We collected the discharge address on our
discharge form, and this was often completed when patients moved from the centre in which they
were recruited. Downstream facilities often did not inform us that the patient had then been
discharged to an address other than their original home address. Our team spent a lot of time
tracking down these patients to obtain their current address.
Anecdotally, patients had often not opened our postal questionnaires because they believed them to
be circulars. Any indication of the content of the letter on the outside of the envelope (e.g. contains
FOCUS trial questionnaires) could have an impact on patient confidentiality and was, therefore,
not used.
l Our 6- and 12-month follow-up questionnaires included the SIS. This is long, containing 59 items in
several domains. In one domain, the Likert scaling for three of the nine items is reversed (i.e. good
outcomes have low instead of high scores in the 1–5 range). Patients found this confusing, and they
often entered internally inconsistent information, which we then queried by telephone.
l The burden of carrying out telephone follow-ups to clarify or complete information received by
post, or to complete the whole follow-up by telephone, was considerable, and was increased as a
result of several factors, including:
¢ Patients changing telephones from landlines to mobiles, which meant that our co-ordinating
team spent a lot of time communicating with centres, downstream health-care facilities, patients’
GPs and proxies to obtain up-to-date contact information.
¢ Patients and proxies increasingly not answering calls from unknown numbers, which are
often assumed to be marketing calls or scams. In many cases, patients or their proxies were
telephoned at different times of the day and week, often on multiple occasions, before contact
was actually made. To overcome this barrier, we often texted the recipient in advance of a phone
call to increase the likelihood that they would answer. In future trials, it would be useful at the
time of recruitment to enter the trial co-ordinating centre’s number into the patients’ and/or
proxies’ mobile phones as a contact so they could make a more informed decision about whether
or not to answer a telephone call from the trial centre.
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
27
l General practitioners and their staff varied greatly in the assistance they would provide in
completing the GP questionnaires and in helping us contact patients. Most were very helpful but:
¢ Some refused to provide information because they were unaware that the patient had provided
written consent for them to do so. We had routinely sent GPs a copy of the patient information
and the completed consent form with a covering letter at the time of recruitment. It appears
that this was often filed and, therefore, it was not obvious to the staff when they received a
request 6 or 12 months later. Some patients had moved house and changed GPs, which meant
that the original trial documentation was not necessarily available to the new GP.
¢ Some GPs reported that they were simply too busy to help.
¢ Some felt that the fee of £54 negotiated with the primary care network was insufficient, and
that they required a much larger sum to complete a follow-up questionnaire. We occasionally
paid a little more, but usually we obtained the data via an alternative route.
Unblinding
The emergency unblinding procedure was carried out for only three patients. One was on the request
of a coroner after the patient died, a second was on the request of the sponsor, for a suspected
unexpected serious adverse reaction, and the third was because the responsible clinician felt that
knowledge of the treatment would significantly alter their management of the patient. All of the
patients had been allocated fluoxetine.
Adherence
The primary measure of adherence was the estimated duration of study medication (interval in days
from first to last dose of study medication) based on all available data. Capsule counts were available
in 398 (25.6%) of those allocated fluoxetine and 410 (26.4%) of those allocated placebo. The patients
returned a median of 32 [interquartile range (IQR) 10–135] capsules in the fluoxetine group and
33 (IQR 11–139) capsules in the placebo group. Our primary measure of adherence was available in
1417 (91%) patients in each group. The median duration of treatment was 185 (IQR 149–186) days in
the fluoxetine group and 183 (IQR 136–186) days in the placebo group. The median delay between
randomisation and first dose was 0 (IQR 0–1) days in both treatment groups. A total of 1519 (97%)
participants in the fluoxetine group and 1494 (96%) participants in the placebo group received their
first dose by day 2 after randomisation (Table 8). Table 9 shows the number and proportion of
patients meeting our eligibility criteria and different levels of adherence to the study medication.
TABLE 8 Number of days from the date of randomisation to the date of starting trial medication
Interval to first dose
Allocated treatment, n (%)
Total, n (%)Fluoxetine Placebo
0 days 817 (52) 816 (52) 1633 (52)
1 day 658 (42) 619 (40) 1277 (41)
2 days 44 (3) 59 (4) 103 (3)
3 days 17 (1) 17 (1) 34 (1)
≥ 4 days 16 (1) 30 (2) 46 (1)
Missing 8 (1) 11 (1) 19 (1)
Total 1564 (100) 1563 (100) 3127 (100)
RESULTS 1: CONDUCT
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Patients stopping the trial medication because of perceived adverse effects within the first 90 days
was only marginally more common in the fluoxetine group (n = 143, 9.1%) than in the placebo group
(n = 122, 7.8%). About two-thirds of patients took the study medication for at least 150 days.
Problems with adherence
We identified some reasons for non-adherence to the trial medication. These included:
l Recruiters not checking that they had someone named on the delegation log who could sign the
initial prescription. Usually this just led to a short delay in starting the medication, but was more
complicated if the patient was discharged or moved hospital prior to receiving the first dose.
l Delays in obtaining the trial medication from pharmacies, especially when the patient was
randomised later in the day.
l In discharge letters to GPs, it was sometimes unclear that patients were in a placebo-controlled
trial and that patient had been given their trial medication. This sometimes led GPs to prescribe
fluoxetine or nursing home staff to ask for fluoxetine to be prescribed on admission or when a
patient’s supply was running low.
l Patients, or their families or nursing home staff, often wanted the trial medication in a blister pack,
in a dosette box provided by pharmacists or in liquid form and so they would then request that the
GPs prescribe fluoxetine – GPs would comply with this. Patients and relatives could put their trial
medication into a dosette box, but we were unable to identify any means of getting pharmacies to
put the trial medication into dosette boxes or blister packs. Thus, some patients allocated to the
placebo group were inadvertently given fluoxetine by their GP.
TABLE 9 Number of trial participants who were ineligible, who had different degrees of adherence and who remained in
the trial after removing ineligible patients and those with poor adherence
Groups cumulatively excluded
Number
meeting each
exclusion
criterion
Cumulative
number
removed
from analysis
Number
remaining in
fluoxetine
group
Number
remaining
in placebo
group
None: as per intention-to-treat analysis 0 0 1553 1553
Ineligible: did not meet all inclusion criteria 11 11 1548 1547
Received no study medication after randomisation 17 26 1540 1540
Received < 90 days of study medication owing to
failure to follow trial procedures
128 152 1480 1474
Received < 90 days of study medication owing to
patient/carer/doctor choice
208 342 1405 1359
Received < 90 days of study medication owing to
suspected adverse reaction
265 607 1262 1237
Allocated placebo but received SSRI for > 10 days
within 90 days
84 628 1262 1216
Allocated fluoxetine and received SSRI for > 10 days
within 90 days
52 651 1239 1216
Received < 150 days of study medication unless died
earlier still taking study medication
847 892 1122 1092
Received < 150 days of study medication for any
reason including death
975 1016 1051 1039
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We introduced a safety alert letter (see www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#)
after patient 1000 was recruited. This was automatically generated when we received the discharge
form (see www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#). The introduction of the safety
fax had no effect on the frequency of inappropriate prescribing of antidepressants, and fluoxetine in
particular, in the randomised patients.
The 24/7 helpline was very helpful in reducing these problems; in many cases, patients, their families
or health-care staff rang the helpline to clarify the situation and we were able to reduce the
non-adherence by talking with all of these groups.
Confirmation of safety outcome events and data cleaning
This was carried out by the data manager and co-chief investigator (MD) prior to unblinding of the
treatment code. We did not have an event or outcome adjudication committee because there is
evidence that these do not significantly improve data quality.58 We aimed to obtain information from
patients, their relatives, GPs and hospitals (usually via the research co-ordinators) to confirm the
event, its nature and its date. We established some rules that were applied so that assumptions
were made consistently.
Monitoring
We monitored the quality and integrity of the accumulating clinical data in accordance with a protocol
agreed with the study sponsors [the Academic and Clinical Central Office for Research and Development
(ACCORD) representing the University of Edinburgh and NHS Lothian], which involved central statistical
monitoring, supplemented by on-site monitoring and detailed source data verification in the co-ordinating
centre and triggered visits when patterns in the data at a centre seemed anomalous. All baseline data
and in-hospital and 6- and 12-month outcome data were subject to verification checks built into the
randomisation and data management system. In practice, almost all monitoring visits to centres were
triggered by the occurrence of protocol deviations and violations, rather than any concerns about
data quality.
Closeout
All trial monitoring activities, including those for trial closure, were carried out in compliance with
the agreed FOCUS monitoring plan and in accordance with the trial sponsor’s standard operating
procedures to ensure that all study-related activities were reconciled, recorded and reported at the
end of the trial in accordance with the trial protocol and all applicable regulatory requirements and
that they complied with good clinical practice.
Remote closeouts were conducted by the FOCUS central team, using a combination of sponsor-approved
checklists (see the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/130430/#; accessed
7 May 2020) and trial-specific instructions and documents for reconciliation of the investigator site file
for completeness. A completed closeout checklist was available for all centres. Bespoke per-site reports
were provided to each site to reconcile all essential documentation required for the investigator site
file in preparation for archiving. The site files included site delegation logs, documentation of staff
qualifications and training (good clinical practice, curricula vitae), IMP management and reconciliation,
consent confirmation, randomisation records, documentation of violations, deviations, serious adverse
events and SUSARs. A final closeout visit to the co-ordinating centre and trial master file review was
conducted by the trial sponsor in preparation for final closure and archiving of all essential trial master
file documents.
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Chapter 4 Results 2: patient outcomes
and events
The main results of the trial have been published.55
The number and percentage of patients in each mRS category by treatment group is shown in Table 10.
The primary outcome at 6 months in the two treatment groups is compared in Figure 3. An ordinal
comparison of the distribution of patients across the mRS at 6 months, adjusted for variables included in
the minimisation algorithm, was similar in the two groups [common odds ratio (COR) 0.951, 95% CI 0.839
to 1.079; p = 0.439], where a COR in favour of placebo is < 1.0. The unadjusted analysis provided similar
results (COR 0.961, 95% CI 0.848 to 1.089; p = 0.531). The ordinal analysis of mRS has been conducted
TABLE 10 Number and percentage of patients in each mRS category by treatment group
Primary outcome
Allocated treatment, n (%)
Fluoxetine Placebo
Disability on the mRS at 6 months
0: no symptoms 114 (7.34) 124 (7.98)
1: no clinically significant disability despite symptoms 302 (19.45) 309 (19.90)
2: slight disability – unable to do everything 156 (10.05) 155 (9.98)
3: moderate disability – unable to live independently but can walk 518 (33.35) 510 (32.84)
4: moderately severe disability and unable to walk without help
from another person
121 (7.79) 122 (7.86)
5: severe disability – unable to sit up 213 (13.72) 203 (13.07)
6: dead 129 (8.31) 130 (8.37)
Total number of patients with mRS 1553 (100.00) 1553 (100.00)
Number of patients with missing mRS 11 10
Total number of patients randomised 1564 1563
0% 10% 20% 30% 40% 50%
Distribution of patients
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mRS category
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FIGURE 3 Comparison of the distribution of patients across the seven categories of the mRS in the two allocated
treatments. Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an
Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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by treatment allocation, under the assumption of proportional odds in the model. This assumption was
found to hold using the score test for proportional odds assumption (p = 0.9947). Comparing the mRS
dichotomised into 0–2 and 3–6, there was similarly little difference between the groups (adjusted OR
0.955, 95% CI 0.812 to 1.123; p = 0.576; unadjusted OR 0.957, 95% CI 0.827 to 1.107; p = 0.352).
The results of our prespecified subgroup analyses are shown in Table 11. There were no statistically
significant interactions between the prespecified subgroups and the effect of treatment on the
primary outcome.
TABLE 11 Primary outcome in prespecified subgroups
6 months, adjusted analysis
Allocated treatment (n)
COR 95% CI p-valueFluoxetine Placebo
Overall 1553 1553 0.952 0.840 to 1.079 0.439
Variables used in the minimisation
Probability of being alive and independent at 6 months
0 to ≤ 0.15 590 586 1.026 0.836 to 1.258 0.326
0.15 to 1 963 967 0.906 0.771 to 1.063
Delay from onset to randomisation (days)
2–8 1061 1067 0.957 0.822 to 1.114 0.951
9–15 492 486 0.940 0.750 to 1.178
Motor deficit
No 203 201 1.207 0.847 to 1.721 0.153
Yes 1350 1352 0.919 0.803 to 1.052
Aphasia
No 1099 1108 0.894 0.770 to 1.038 0.123
Yes 454 445 1.107 0.874 to 1.403
Other prespecified subgroup analyses
Stroke type
Haemorrhagic 153 156 0.816 0.546 to 1.221 0.427
Ischaemic 1400 1397 0.969 0.848 to 1.107
Age group (years)
≤ 70 661 661 0.947 0.780 to 1.151 0.944
> 70 892 892 0.952 0.806 to 1.124
Who gave consent
Proxy 427 443 0.944 0.741 to 1.204 0.899
Patient 1126 1110 0.940 0.810 to 1.092
Inability to assess mood
No 1167 1165 0.891 0.770 to 1.031 0.089
Yes 386 388 1.125 0.871 to 1.452
Baseline depression
No 1457 1483 0.952 0.836 to 1.084 0.805
Yes 96 70 1.030 0.586 to 1.798
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Table 12 shows the effect of fluoxetine on our primary outcome in subgroups defined by their meeting
the eligibility criteria and being adherent to the study medication to different degrees (see Table 9).
These are a series of prespecified per-protocol analyses that sequentially exclude subgroups of patients
who either did not meet our eligibility criteria or had incomplete adherence to the study medication.
There was no trend towards greater benefit in those with greater adherence.
Table 13 shows the safety outcomes at 6 months. Those allocated fluoxetine were less likely to
be diagnosed with a new episode of depression [n = 210 (13.0%) vs. n = 269 (16.9%), difference in
proportion –3.78%, 95% CI –1.26% to –6.30%; p = 0.003]. Those allocated fluoxetine had an increased
risk of fractures [n = 45 (2.9%) vs. n = 23 (1.5%), difference in proportion 1.41%, 95% CI 0.38% to
2.43%; p = 0.007]. There were no statistically significant differences in other safety outcomes, although
there were expected trends towards more events in the fluoxetine group for adverse effects listed in
the SmPC for fluoxetine [epileptic seizures, falls, hyponatraemia (Na+ < 125 mmol/l – reported by
treating clinician) and markers of poor diabetic control] (see the project web page: www.journalslibrary.
nihr.ac.uk/programmes/hta/130430/#; accessed 7 May 2020). There were only small differences in
the rates of thrombotic and bleeding events (Table 14) despite concerns that fluoxetine might affect
platelet function and interact with antithrombotic medications.
We also carried out a safety analysis, which analysed patients according to the treatment they received
rather than the treatment they were allocated. These data are provided in Report Supplementary Material 3.
The other secondary outcomes (fatigue, mood, HRQoL and SIS) are compared in Tables 15 and 16. Those
treated with fluoxetine had better mood measured on the MHI-5 at the 6-month follow-up than those
allocated placebo [median 76 (IQR 60–88) vs. 72 (IQR 56–88); p = 0.010]. This is consistent with the
TABLE 12 Effect of fluoxetine on the primary outcome in patients after exclusion of ineligible patients, and those with
different degrees of non-adherence (see Table 9)
Groups cumulatively excluded
Number
remaining in
fluoxetine
group
Number
remaining
in placebo
group
COR for
mRS 95% CI p-value
None: as per intention-to-treat analysis 1553 1553 0.951 0.839 to 1.079 0.439
Ineligible: did not meet all inclusion criteria 1548 1547 0.949 0.837 to 1.077 0.418
Received no study medication after
randomisation
1540 1540 0.948 0.835 to 1.076 0.406
Received < 90 days of study medication owing
to failure to follow trial procedures
1480 1474 0.958 0.842 to 1.090 0.514
Received < 90 days of study medication owing
to patient/carer/doctor choice
1405 1359 0.912 0.797 to 1.042 0.175
Received < 90 days of study medication owing
to suspected adverse reaction
1262 1237 0.936 0.813 to 1.078 0.360
Allocated placebo but received SSRI for
> 10 days within 90 days
1262 1216 0.923 0.801 to 1.064 0.268
Allocated fluoxetine and received SSRI for
> 10 days within 90 days
1239 1216 0.927 0.804 to 1.068 0.294
Received < 150 days of study medication unless
died earlier still taking study medication
1122 1092 0.888 0.765 to 1.032 0.121
Received < 150 days of study medication for
any reason including death
1051 1039 0.921 0.788 to 1.075 0.296
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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TABLE 13 Safety outcomes at 6 months
Adverse events by 6 months
Allocated treatment, n (%)
Difference (%) 95% CI (%) p-valueFluoxetine Placebo
Epileptic seizures 58 (3.71) 40 (2.56) 1.15 –0.07 to 2.37 0.065
Fall with injury 120 (7.67) 94 (6.01) 1.66 –0.11 to 3.43 0.066
Fractured bone 45 (2.88) 23 (1.47) 1.41 0.38 to 2.43 0.007
Hyponatraemia Na+ < 125mmol/l 22 (1.41) 14 (0.90) 0.51 –0.24 to 1.26 0.181
Hyperglycaemia 23 (1.47) 16 (1.02) 0.45 –0.33 to 1.22 0.260
Symptomatic hypoglycaemia 23 (1.47) 13 (0.83) 0.64 –0.11 to 1.39 0.094
New depression 210 (13.43) 269 (17.21) –3.78 –6.30 to –1.26 0.003
New antidepressant prescription 280 (17.90) 357 (22.84) –4.94 –7.76 to –2.12 0.001
Attempted/actual suicide 3 (0.19) 2 (0.13) 0.06 –0.02 to 0.34 0.655
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 14 Recurrent strokes, thrombotic and haemorrhagic events by 6 months
Adverse events by 6 months
Allocated treatment, n (%)
Difference (%) 95% CI (%) p-valueFluoxetine Placebo
Any stroke 56 (3.58) 64 (4.09) –0.51 –1.86 to 0.83 0.454
All thrombotic events 78 (4.99) 92 (5.89) –0.90 –2.49 to 0.69 0.268
Ischaemic stroke 43 (2.75) 45 (2.88) –0.13 –1.29 to 1.03 0.826
Other thrombotic events 20 (1.28) 27 (1.73) –0.45 –1.30 to 0.40 0.303
Acute coronary events 15 (0.96) 23 (1.47) –0.51 –1.28 to 0.26 0.191
All bleeding events 41 (2.62) 38 (2.43) 0.19 –0.91 to 1.29 0.735
Haemorrhagic stroke 7 (0.45) 9 (0.58) –0.13 –0.60 to 0.37 0.615
Upper gastrointestinal bleed 21 (1.34) 16 (1.02) 0.32 –0.44 to 1.08 0.409
Other major bleeds 13 (0.83) 14 (0.90) –0.06 –0.71 to 0.58 0.845
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 15 Secondary outcomes at 6 months: fatigue, mood and HRQoL
Outcome
Allocated treatment
p-value
(Mann–Whitney
U-test)
Fluoxetine Placebo
Missing (n) Median IQR Missing (n) Median IQR
Vitality subscale
of SF-36
19 56.25 37.5–75.00 21 56.25 43.75–56.25 0.673
MHI-5 26 76.00 60.00–88.00 22 72.00 56.00–88.00 0.010
EQ-5D-5L 12 0.56 0.21–0.74 4 0.56 0.19–0.75 0.587
Patients who had died are excluded from the missing data. Higher values are associated with better outcome.
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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lower rate of new episodes of depression that we observed. There were no statistically significant
differences in any other secondary outcomes at 6 months, including any of the nine domains of the SIS,
the vitality subscale of the SF-36 and the EQ-5D-5L.
The number and percentage of patients in each mRS category at the 12-month follow-up by treatment
group is shown in Table 17. An ordinal comparison of the distribution of patients across the mRS at
12 months, adjusted for variables included in the minimisation algorithm, was similar in the two
groups (COR 1.015, 95% CI 0.894 to 1.151; p = 0.820), where a COR in favour of placebo is < 1.0.
The unadjusted analysis provided similar results (COR 1.011, 95% CI 0.892 to 1.145; p = 0.866). When
TABLE 16 Secondary outcomes at 6 months: SIS
SIS domain
Allocated treatment
p-value
(Mann–Whitney
U-test)
Fluoxetine Placebo
Missing (n) Median IQR Missing (n) Median IQR
Strength 13 56.25 31.25–81.25 14 62.50 37.50–81.25 0.701
Hand ability 14 45.00 0.00–90.0 18 50.00 0.00–90.00 0.482
Mobility 9 63.89 36.11–86.11 7 63.89 33.33–88.89 0.549
Motor 12 54.86 27.31–83.33 13 56.78 28.75–82.64 0.513
Daily activities 11 62.50 37.50–90.00 13 65.00 35.00–90.00 0.624
Physical function 11 56.77 30.38–84.31 12 58.82 30.56–84.10 0.515
Memory 23 82.14 57.14–96.43 18 82.14 57.14–96.43 0.307
Communication 12 89.29 67.86–100 11 92.86 71.43–100.0 0.192
Emotion 42 75.00 58.33–88.89 29 75.00 58.33–88.89 0.469
Participation 12 62.50 37.50–87.50 15 65.63 40.63–87.50 0.260
Recovery (VAS) 16 60.00 40.00–80.00 9 60.00 40.00–80.00 0.982
VAS, visual analogue scale.
Patients who had died are excluded from the missing data. Higher values are associated with better outcome.
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 17 Distribution of mRS categories at 12-month follow-up
mRS at 12 months
Allocated treatment, n (%)
Fluoxetine Placebo
0 133 (8.64) 145 (9.39)
1 251 (16.31) 237 (15.35)
2 178 (11.57) 175 (11.33)
3 494 (32.10) 505 (32.71)
4 90 (5.85) 81 (5.25)
5 211 (13.71) 203 (13.15)
6 (dead) 182 (11.83) 198 (12.82)
Missing mRS 25 19
Total number of patients randomised 1564 1563
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comparing the mRS dichotomised into 0–2 and 3–6, there was similarly little difference between the
groups (adjusted OR 1.033, 95% CI 0.879 to 1.215; p = 0.691; unadjusted OR 1.019, 95% CI 0.880 to
1.181; p = 0.799).
The survival of patients in the two treatment groups is compared in Figure 4. Anyone who died after
1 year was considered to be alive and censored at 365 days and any participant who withdrew consent
was considered to be alive and was censored at the time of withdrawal. There was no statistically
significant difference in the hazards of death over the first 12 months after randomisation (HR 0.929,
95% CI 0.756 to 1.141; p = 0.482) adjusted for baseline variables.
Table 18 shows the number of patients with a new episode of depression or who had started an
antidepressant between randomisation and 12 months. The difference in the cumulative number of
patients diagnosed with a new episode of depression over the 12 months between the two treatment
groups was no longer statistically significant. More patients had been started on antidepressants in the
placebo group than in the fluoxetine group, but some were started on antidepressants for indications
other than depression.
TABLE 18 New depression and new antidepressant medication by 12 months
Outcome by 12 months
Allocated treatment, n (%)
Difference (%) 95% CI (%) p-valueFluoxetine Placebo
New depression 292 (18.67) 327 (20.92) –2.25 –5.04 to 0.54 0.114
New antidepressant prescription 358 (22.89) 410 (26.23) –3.34 –6.36 to –0.33 0.030
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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FIGURE 4 The Kaplan–Meier survival curves for the two allocated treatments with number of subjects at risk. Times
have been capped at 365 days. Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by
Elsevier Ltd. This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY-NC-ND 4.0) license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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The difference in MHI-5 scores between the groups at 6 months was not sustained at 12 months
(Table 19), and there were no statistically significant differences between treatment groups in vitality
or HRQoL at 12 months.
The SIS scored in the two treatment groups at 12 months is shown in Table 20. There was little
difference between the treatment groups on any of the domains.
TABLE 20 Secondary outcomes at 12 months: SIS
SIS domain
Allocated treatment
p-value
(Mann–Whitney
U-test)
Fluoxetine Placebo
Missing (n) Median IQR Missing (n) Median IQR
Strength 35 56.25 31.25–75.00 31 56.25 37.50–75.00 0.384
Hand ability 34 50.00 0.00–90.00 33 50.00 5.00–90.00 0.281
Mobility 28 66.67 36.11–88.89 29 66.67 38.89–88.89 0.543
Motor 33 55.56 28.80–83.33 31 58.61 31.20–83.70 0.329
Daily activities 30 67.50 40.00–90.00 33 67.50 40.00–90.00 0.581
Physical function 30 57.81 32.81–84.24 31 60.10 33.54–85.28 0.372
Memory 33 78.57 60.71–96.43 32 82.14 57.14–96.43 0.425
Communication 32 89.29 67.86–100.0 29 89.29 71.43–100.0 0.314
Emotion 46 72.22 58.33–86.11 44 73.61 58.33–88.89 0.744
Participation 32 65.63 40.63–90.63 33 65.63 40.63–90.63 0.930
SIS recovery
(VAS)
24 60.00 40.00–80.00 24 60.00 40.00–80.00 0.933
VAS, visual analogue scale.
Higher values are associated with better outcome.
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
TABLE 19 Secondary outcomes at 12 months: fatigue, mood and HRQoL
Outcome
Allocated treatment
p-value
(Mann–Whitney
U-test)
Fluoxetine Placebo
Missing (n) Median IQR Missing (n) Median IQR
Vitality subscale
of SF-36
31 50.00 37.50–75.00 35 50.00 37.50–75.00 0.904
MHI-5 34 72.00 56.00–88.00 36 76.00 56.00–88.00 0.711
EQ-5D-5L
excluding
dead patients
18 0.59 0.24–0.75 13 0.59 0.27–0.77 0.309
Higher values are associated with better outcome.
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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We assessed the effect of treatment among the subgroup with motor deficit at baseline (n = 2722) and
among those who had a mRS at 6 months (n = 2702) but found no evidence of an effect on the mRS
(p = 0.2172). Of the 2722 participants who had a motor deficit at baseline, 2438 had a motor score
outcome [fluoxetine median 48.43 (IQR 24.98–78.84) vs. placebo median 52.66 (IQR 25.28–77.22);
p = 0.471]. In addition, in the 906 patients with aphasia at baseline, 899 had a mRS at 6 months
and 794 had a SIS communication domain score at 6 months. There was little difference in the mRS
(see Table 11) or SIS communication scores between the treatment groups [fluoxetine median 64.29
(IQR 32.14–89.29) vs. placebo 64.29 (IQR 35.71–89.29); p = 0.497].
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Chapter 5 Results 3: post hoc analyses to
better understand the observed effect of
fluoxetine on the risk of bone fractures
Introduction
The statistically significant excess of bone fractures (see Table 13) that we observed is potentially
important for several reasons. First, many observational studies have demonstrated an association
between SSRI use and fractures.27,28 However, the question of whether or not this association is causal
has remained. RCTs provide stronger evidence of causality than any other research method. Second, if
fractures affect patients’ functional outcomes, then this excess might have offset some beneficial effects
of fluoxetine on functional outcomes. Third, if SSRIs, and fluoxetine specifically, cause fractures, the
following question arises: what are the mechanisms by which they have this effect? Is it owing to an
increased risk of falling, which could be through several possible mechanisms, or the proposed effects
of SSRIs on bone density, or both, or neither?
We have, therefore, carried out some post hoc analyses in an attempt to answer the following
questions:
l What sort of fractures occurred after stroke and were they likely to have had an impact on
patients’ function?
l Might the increased risk of fractures, along with their associated loss of function, have offset the
beneficial effects of fluoxetine on neurological recovery?
l What baseline factors were associated with fracture risk?
l Does the temporal pattern of fractures in the FOCUS trial provide any useful information about the
relative importance of the potential mechanisms of SSRI-induced fractures?
Methods
We have published a brief account of further analyses and results that attempts to address these
questions.59 We extracted further information from our trial database while remaining blind to
treatment allocation. Here we present the post hoc analyses in more detail. Having identified the
excess risk of bone fractures in our prespecified analyses,52 we also prespecified further analyses to
address our additional research questions about fractures. We coded baseline medications to distinguish
non-SSRI antidepressants, blood pressure lowering, bone density reducing (e.g. glucocorticoids) or
bone density increasing (e.g. calcium, vitamin D and bisphosphonates) medications and those that might
increase risk of falls (e.g. tranquillisers). In addition, we extracted available data on the fracture site and
any associated falls or seizures. We had not systematically collected data that indicated the side of the
body where fracture(s) occurred. We compared the number of fractures occurring in those with and
without specific characteristics but formally tested each variable by plotting Kaplan–Meier survival
curves in those with and without each characteristic and compared these with the log-rank statistic.
We did not formally test differences in fracture risk where numbers were small (i.e. fewer than six).
We included all variables with a p-value of < 0.1 into a Cox proportional hazards model to identify
independent predictors of fracture risk. We repeated these analyses focusing on fractures only at
sites typically associated with low bone density (i.e. neck of femur, wrist and vertebrae).
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Results
Type of fractures
In our original published analysis of fractures,55 we included 68 patients with at least one fracture each
(see Table 13), where the fracture had been diagnosed on radiography after randomisation. However, in
three patients, on reviewing all of the evidence, the fracture had probably occurred before randomisation.
We excluded these patients (two from the fluoxetine group and one from the placebo group) from
further analyses. Sixty-five of the 3127 (2.1%) patients who were enrolled had 67 definite new fractures
(two patients sustained more than one fracture simultaneously) within 6 months of randomisation.
The differences in fracture risk between the fluoxetine and the placebo group remained statistically
significant (in a univariate analysis) having removed the three patients [43 (2.75%) vs. 22 (1.41%);
difference 1.34%, 95% CI 0.34% to 2.34%; p = 0.009]. Among the 65 patients with fractures, 59 (90.8%)
fractures resulted from a fall. The sites of the fractures are shown in Table 21; 26 patients (40%) had a
neck of femur fracture, which was quite likely to have had an impact on patients’ functional outcome.
Effect of removing the patients with fracture from estimates of effect on modified
Rankin Scale
Removing the 65 patients with at least one fracture during follow-up from the primary analysis (ordinal
imbalance) did not significantly alter the estimate of effect of fluoxetine on the mRS (COR including
those with fractures 0.951, 95% CI 0.839 to 1.079; p = 0.439; COR for those without fractures 0.961,
95% CI 0.847 to 1.093; p = 0.545).59
Risk factors for fractures
Those who had a fracture within 6 months were older [mean age 76 (SD 12.2) vs. 71 (SD 11.6) years,
difference 4.9 years, 95% CI for difference 2.0 to 7.9 years; p = 0.001] and had slightly more severe
strokes [median NIHSS 7.0 (IQR 4–11) vs. 6.0 (IQR 3–11); p = 0.407]. The numbers (%) of patients with
specific baseline characteristics divided into those with and without subsequent fractures are shown in
Table 22, along with the p-value for the difference based on the log-rank analysis of the Kaplan–Meier
curves. The differences were statistically significant only between those aged > 70 years and younger
patients, between women and men and between those allocated to fluoxetine and those allocated to
TABLE 21 The site of fractures and associated events occurring between randomisation and 6-month follow-up
Fracture-related outcome Number %
Number of patients sustaining a fracture 65
Number of fractures sustained 67 100.0
Site of fracture
Neck of femur 26 40.0
Vertebral 10 15.4
Any long bone 10 15.4
Wrist 7 10.8
Rib 4 6.2
Pelvis 3 4.6
Clavicle 1 1.5
Other (e.g. skull and patella) 6 9.2
Site associated with osteoporosis 40 61.5
Associated with a fall 59 90.8
Associated with an epileptic seizure 1 1.5
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TABLE 22 The number and percentage with each baseline characteristic in those patients with and without a fracture
within 6 months of randomisation
Characteristic
Fracture by 6 months, n (%)
Log-rank statisticNo Yes
Total number of patients randomised 3062 (100.0) 65 (100.0)
Randomised treatment
Fluoxetine 1521 (49.7) 43 (66.2) 0.008
Placebo 1541 (50.3) 22 (33.9)
Sex
Female 1167 (38.1) 38 (58.5) 0.001
Male 1895 (61.9) 27 (41.5)
Age group (years)
≤ 70 1313 (42.9) 17 (26.2) 0.003
> 70 1749 (57.1) 48 (73.9)
Before the stroke
Dependent in ADL 253 (8.3) 8 (12.3) 0.176
Ischaemic stroke/TIA 557 (18.2) 11 (16.9) 0.882
Diabetes 628 (20.5) 12 (18.5) 0.760
Bone fractures 486 (15.9) 11 (16.9) 0.829
Depression 244 (8.0) 9 (13.9) 0.091
Stroke type
Intracerebral haemorrhage 301 (9.8) 10 (15.4) 0.132
Stroke deficits at baseline
Unable to walk 2227 (72.7) 53 (81.5) 0.085
Unable to lift both arms 1243 (40.6) 25 (38.5) 0.870
Unable to talk 779 (25.4) 18 (27.7) 0.520
Motor deficit on NIHSS 2665 (87.0) 57 (87.7) 0.797
Visual field deficit on NIHSS 844 (27.6) 14 (21.5) 0.326
Limb ataxia on NIHSS 753 (24.6) 17 (26.2) 0.832
Baseline medications
Non-SSRI antidepressant 137 (4.5) 5 (7.7)
Treatments for osteoporosis 287 (9.4) 5 (7.7)
Major or minor tranquillisers 121 (4.0) 3 (4.6)
Parkinson’s disease medication 14 (0.5) 2 (3.1)
BP-lowering medication 2178 (71.1) 52 (80.0) 0.100
Treatments for vertigo 129 (4.2) 5 (7.7)
Any of these drugs of interest 2349 (76.7) 55 (84.6) 0.116
ADL, activities of daily living; BP, blood pressure.
Notes
The log-rank statistic tests the statistical significance of the difference in Kaplan–Meier survival curves (measuring time
to fracture) between those with and without these characteristics. No log-rank test was carried out where the
characteristic was present in fewer than six patients.
Reproduced from Dennis et al.59 © American Heart Association, Inc.
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
41
placebo. Medical history including prior fractures, stroke pathology, NIHSS, type of deficit and
medications of different types had no statistically significant associations with fracture risk. Previous
depression and being able to walk at the time of the stroke did not reach the 5% level of significance;
however, they were included in our Cox proportional hazards model as they were approaching
significance (p < 0.1).
The Cox proportional hazards model with all those variables reaching and approaching statistical
significance is shown in Table 23.
When those variables that do not reach statistical significance at the 5% level are sequentially
removed, the resulting Cox model (Table 24) contained just three variables: sex, age group and
randomised treatment.
The Cox proportional hazards model (see Table 23) showed that only age of > 70 years (HR 1.97,
95% CI 1.13 to 3.45; p = 0.017), female sex (HR 2.131. 95% CI 1.294 to 3.511; p = 0.003) and fluoxetine
treatment (HR 2.00, 95% CI 1.196 to 3.344; p = 0.008) were independent predictors of fracture.
The model was almost identical when only those with fractures at sites likely to be affected by
osteoporosis (i.e. neck of femur, vertebral and wrist) were included.
Temporal pattern of fractures
The Kaplan–Meier curve comparing fracture risk in the two treatment groups is shown in Figure 5. The
risks appear to diverge early after randomisation, which might suggest that an increased risk of falling
associated with taking fluoxetine contributed to the excess of fractures. A delayed divergence might
have suggested that the excess was mainly owing to effects on bone density, which presumably would
not have occurred immediately.
TABLE 23 Cox proportional hazards model with all variables reaching or approaching statistical significance in univariate
analysis (see Table 22)
Parameter Value Probability> χ2 HR HR 95% CI
Sex Female 0.008 1.978 1.193 to 3.280
Age group > 70 years 0.018 1.973 1.123 to 3.467
Previous depression No/unknown 0.135 0.581 0.285 to 1.184
Able to walk No 0.240 1.462 0.776 to 2.755
Randomised treatment Fluoxetine 0.009 1.992 1.191 to 3.330
TABLE 24 Final Cox proportional hazards model showing factors predictive of a fracture
Parameter Value Probability> χ2 HR HR 95% CI
Sex Female 0.003 2.131 1.294 to 3.511
Age group > 70 years 0.017 1.972 1.127 to 3.451
Randomised treatment Fluoxetine 0.008 2.000 1.196 to 3.344
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FIGURE 5 Kaplan–Meier curves to 6 months, with number of subjects at risk, comparing the risk of fracture in those
allocated fluoxetine and placebo where patients dying or being lost to follow-up were censored. Reproduced from
Dennis et al.59 © American Heart Association, Inc.
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Chapter 6 Results 4: health economic
evaluation
Introduction
We undertook a within-trial economic analysis to estimate the cost-effectiveness of fluoxetine on an
intention-to-treat basis. The primary treatment effect in the economic analysis was estimated using an
individual-level regression model for average (mean) incremental costs and incremental survival times
over 12 months after randomisation.
Methods
Resource use and costs
The number and duration of hospital stays and other secondary care contacts were recorded using
information obtained from the case report form. We had planned to use data from NHS Digital in
England and Wales, and from eDRIS for patients recruited in Scotland, but we were unable to obtain
these data in time to produce analyses that could be included in this report.
Unit costs and analysis
We converted length-of-stay distributions into cost estimates based on a per-diem hospital cost.
Resource use was valued from the perspective of the NHS using the 2017/18 and 2018/19 national
tariffs with currencies and prices for 2018.60 Per-diem hospital costs were derived using tariff
information for Healthcare Resource Group codes AA22C to AA22G (Cerebrovascular Accident,
Nervous System Infections or Encephalopathy) with varying levels of complexity and complications.60
Our base case simulated unit costs using a gamma distribution around a mean of £515 per day
with higher unit costs for the first 2 days to allow for conditional payments (best-practice tariffs) for
acute stroke care (i.e. direct admissions to an acute stroke unit, initial brain imaging and thrombolysis
assessment). We also considered other cost distributions, including the application of trim points for
lengths of hospital stay beyond 63 days with lower unit costs of £240 per day. The results from the
sensitivity analysis were quantitatively and qualitatively similar to those of the base-case analysis,
so are not reported. Other secondary care contacts were costed using corresponding currencies and
prices from the national tariff. The NHS indicative price for 20-mg capsules of fluoxetine was £2.27
for 30 capsules.61 No discounting of resource costs was conducted as the time horizon was limited
to 12 months for within-trial analysis.
Health outcomes
Survival times for the first 12 months after randomisation were measured in days, with anyone alive at
365 days being censored. Self-reported HRQoL at 6 and 12 months of follow-up was measured using
the EQ-5D-5L preference-based scale. The EQ-5D-5L index values were calculated using English value
sets. We also validated the EQ-5D-5L by checking the concordance with the mRS. We planned to use
a standard multiplicative model to estimate quality-adjusted survival (QALYs) calculated by the area
under linear interpolation of the EQ-5D-5L index value trajectory for each individual with survival
times, the EQ-5D-5L utility index value at 6 and 12 months and a modelled baseline EQ-5D-5L utility
index value. If no group differences in the EQ-5D-5L emerged, QALYs would not be estimated and the
analysis would focus on any difference in survival days.
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Cost-effectiveness model specification
The primary treatment effect in the economic analysis was estimated using an individual-level
regression model for average (mean) incremental costs and incremental survival times over 12 months
after randomisation. The model accounts for the joint distribution of costs and survival times using a
general specification that allowed for different parametric and conditional distributions. Incremental
cost-effectiveness ratios (ICERs) are reported for the difference in mean total costs between treatment
groups divided by the difference in mean number of survival days between treatment groups. All
analyses were based on cases with complete information on resource use and survival times.
Sensitivity analysis
Mean costs and survival times and differences between intervention treatment groups in costs and survival
times were based on a bootstrapped analysis using 1000 (and 10,000) replicates. Uncertainty in the ICER
was visually represented as a cost-effectiveness plane. Incremental net benefits and cost-effectiveness
acceptability curves were not calculated if the ICER was centred on zero (i.e. no difference in mean costs
and survival times). We conducted a companion analysis of cost-effectiveness in which we truncated the
cumulative cost distribution at 6 months and estimated the incremental costs in relation to incremental
differences in the primary outcome (mRS at 6 months).
Long-run economic analysis and assessment of treatment effect heterogeneity
Longer-run modelling, estimating the distribution of costs and quality-adjusted survival times
calculated over the expected patient lifetimes, was planned if differences in the primary outcome
emerged between treatment groups at 6 months. Our intention was to use a microsimulation model
calibrated using information gained from the within-trial analysis of cost-effectiveness combined with
additional data from (1) Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) and EFFECTS,62
(2) trials and observational studies reporting longer-term costs, survival and HRQoL following stroke,
and (3) expert beliefs on the distributions of parameters where information was less readily available.
Secondary analyses are planned to address heterogeneous treatment effects using the pooled individual-
level data from FOCUS, AFFINITY and EFFECTS.62 Subpopulations with different average treatment
effects will be identified using ‘regression tree’ or ‘recursive partitioning’ methods. These data-driven
analyses complement prespecified subgroup analyses examining individual and group covariates of
substantive interest, such as stroke severity (NIHSS) and the six simple variable model for prognosis.31
Results
Resource use and cost analysis
Hospital inpatient use and attendances and duration of fluoxetine therapy are reported in Table 25.
At 12 months, the average number of inpatient hospital days was just over 30 days for both treatment
groups, with little difference in the average number of hospital attendances. Fluoxetine therapy lasted
143 days on average, with a median of 6 months. The distributions of cumulative total costs (Table 26)
TABLE 25 Hospital resource use within 12 months of randomisation by allocated treatment
Resource use
Allocated treatment
Fluoxetine (n= 1556) Placebo (n= 1553)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Hospital inpatient days 32 (39) 16 (5–46) 31 (39) 15 (4–43)
Hospital attendances 0.343 (0.582) 0 (0–1) 0.338 (0.605) 0 (0–1)
Fluoxetine therapy (days) 143 (64) 182 (101–186) 0 0
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were similar between the groups, with mean total costs of £18,784 (median £11,150) for patients
allocated to fluoxetine and £18,297 (median £10,871) for patients allocated to placebo.
Health outcomes
Mean survival times up to 12 months were 334 days (11 months) for both treatment groups. The
pattern and distribution of EQ-5D-5L dimensions and levels were similar at 6 months, with little change
at 12 months (Table 27). The frequency of ‘no problems’ (i.e. level 1) and ‘problems’ (i.e. levels 2 to 5)
across the five dimensions at 6 months revealed a slight advantage in mobility and usual activity for
the placebo group and less anxiety and depression in the fluoxetine group. These differences diminished
by 12 months. The 10 most frequent EQ-5D-5L profiles accounted for around one-fifth of profiles
and there was a high degree of concordance between treatment groups at 6 and 12 months (Table 28).
EQ-5D-5L index values averaged around 0.47 at 6 months with no significant difference between the
treatment groups; at 12 months, there was a slight increase in the mean index value to 0.50 but no sign
of difference between patients allocated to fluoxetine or placebo (Table 29). Given the similar survival
trajectories and EQ-5D-5L index values up to 12 months, there is no evidence of a difference in
quality-adjusted survival times.
Cost-effectiveness
Table 30 and Figure 6 present the cost-effectiveness results at 12 months. Although there is a slight
difference of around £500 in the mean total costs and a very small increase (< 1 day) in survival times
for the fluoxetine group, neither of these differences are significant. The ICER of £2609 per day is not
significantly different from zero, as illustrated in the cost-effectiveness plane (see Figure 6). The joint
distribution of incremental costs and incremental survival days is essentially centred on zero.
Finally, given the statistically significant increase in fracture risk at 6 months in the fluoxetine group,
exploratory analysis suggests that this is likely to account for around 37% of the difference in mean
total costs reported above as patients who sustained a fracture reported a £13,330 (95% CI £8453 to
£18,207) increase in mean total costs at 12 months.
TABLE 26 Cumulative health-care total costs within 12 months of randomisation by allocated treatment
Cost (£)
Allocated treatment
Fluoxetine (n= 1548) Placebo (n= 1553)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Hospital inpatient days 18,561 (20,502) 10,870 (5113–26,195) 18,137 (20,214) 10,632 (4805–24,855)
Hospital attendances 162 (277) 0 (0–405) 159 (289) 0 (0–397)
Fluoxetine therapy 11 (5) 14 (8–14) 0 0
Total costs 18,784 (20,504) 11,150 (5231–26,400) 18,297 (20,201) 10,871 (5129–24,855)
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TABLE 27 Distribution of EQ-5D-5L dimensions and levels at 6 and 12 months by allocated treatment
Dimension Level
6 months (%) 12 months (%)
Allocated treatment
Total
(N= 2835)
Allocated treatment
Total
(N= 2672)
Fluoxetine
(n= 1413)
Placebo
(n= 1422)
Fluoxetine
(n= 1339)
Placebo
(n= 1333)
Mobility No problems 17.8 21.4 19.6 19.5 21.5 20.5
Slight problems 23.4 22.9 23.1 24.5 22.7 23.6
Moderate
problems
24.6 23.0 23.8 25.7 26.0 25.9
Severe problems 17.5 17.5 17.5 16.1 15.8 15.9
Unable to 16.8 15.2 16.0 14.3 13.9 14.1
Self-care No problems 37.1 37.1 37.1 37.9 39.4 38.7
Slight problems 19.4 19.8 19.6 21.4 20.5 20.9
Moderate
problems
19.3 18.0 18.7 18.8 16.1 17.4
Severe problems 8.5 8.2 8.4 7.5 9.1 8.3
Unable to 15.7 16.8 16.3 14.4 15.0 14.7
Usual
activity
No problems 14.8 17.3 16.1 17.9 17.5 17.7
Slight problems 22.1 21.6 21.8 21.1 25.2 23.2
Moderate
problems
20.2 18.5 19.4 22.8 19.7 21.3
Severe problems 13.4 14.5 13.9 13.8 13.7 13.7
Unable to 29.5 28.1 28.8 24.4 23.9 24.1
Pain/
discomfort
No pain 36.4 37.2 36.8 35.8 36.7 36.2
Slight pain 29.3 28.3 28.8 30.8 33.3 32.1
Moderate pain 24.6 24.1 24.3 23.1 21.5 22.3
Severe pain 7.9 8.0 7.9 7.5 6.8 7.2
Extreme pain 1.9 2.3 2.1 2.8 1.7 2.2
Anxiety/
depression
Not anxious 53.4 49.0 51.2 45.6 47.6 46.6
Slightly anxious 25.3 26.9 26.1 34.6 31.7 33.1
Moderately
anxious
16.0 17.7 16.8 14.4 15.8 15.1
Severely anxious 3.9 4.7 4.3 3.9 3.7 3.8
Extremely anxious 1.4 1.8 1.6 1.6 1.4 1.5
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TABLE 28 The 10 most frequent EQ-5D-5L profiles at 6 and 12 months by allocated treatment
Rank
Allocated treatment
Fluoxetine Placebo
EQ-5D-5L profile n % % (cumulative) EQ-5D-5L profile n % % (cumulative)
Analysis at 6 months
1 1 1 1 1 1 90 6.3 6.3 1 1 1 1 1 105 7.4 7.4
2 2 1 2 1 1 34 2.4 8.7 1 1 2 1 1 33 2.3 9.7
3 2 1 2 2 1 30 2.1 10.8 2 1 2 1 1 31 2.2 11.9
4 5 5 5 1 1 29 2.0 12.8 1 1 1 2 1 27 1.9 13.7
5 1 1 2 1 1 27 1.9 14.7 2 1 2 2 1 23 1.6 15.4
6 2 1 1 1 1 25 1.8 16.5 5 5 5 1 1 21 1.5 16.8
7 1 1 1 2 1 17 1.2 17.7 2 2 2 1 1 19 1.3 18.2
8 5 5 5 2 1 16 1.1 18.8 5 5 5 2 1 18 1.3 19.4
9 5 5 5 2 2 16 1.1 19.9 1 1 1 1 2 16 1.1 20.6
10 2 2 2 2 1 14 1.0 20.9 2 1 1 1 1 16 1.1 21.7
Total 1425 100.0 1426 100.0
Analysis at 12 months
1 1 1 1 1 1 105 7.7 7.7 1 1 1 1 1 102 7.6 7.6
2 1 1 1 2 1 29 2.1 9.9 1 1 2 1 1 35 2.6 10.2
3 2 1 1 1 1 25 1.8 11.7 2 1 2 2 1 32 2.4 12.6
4 1 1 2 1 1 21 1.6 13.3 1 1 1 2 1 27 2.0 14.6
5 5 5 5 2 2 21 1.6 14.8 2 1 2 1 1 26 1.9 16.5
6 2 1 2 2 1 20 1.5 16.3 5 5 5 2 2 22 1.6 18.1
7 5 5 5 3 3 20 1.5 17.8 1 1 2 1 2 20 1.5 19.6
8 2 1 2 1 1 19 1.4 19.2 2 1 1 1 1 20 1.5 21.1
9 2 2 2 2 2 19 1.4 20.6 2 1 1 2 1 17 1.3 22.4
10 2 1 2 2 2 18 1.3 21.9 1 1 2 2 1 16 1.2 23.6
Total 1357 100.0 1346 100.0
TABLE 29 The EQ-5D-5L index values at 6 and 12 months by allocated treatment
EQ-5D-5L index
Allocated treatment
Mean difference (95% CI) p-value
Fluoxetine Placebo
n Mean (SD) n Mean (SD)
6 months 1413 0.470 (0.358) 1422 0.475 (0.360) –0.005 (–0.031 to 0.022) 0.716
12 months 1339 0.491 (0.357) 1333 0.505 (0.352) –0.013 (–0.040 to 0.014) 0.330
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TABLE 30 Cost-effectiveness results
Outcome
Allocated treatment
Mean difference (95% CI) p-value
Fluoxetine Placebo
n Mean (SD) n Mean (SD)
Total costs (£) 1548 18,784 (20,504) 1553 18,297 (20,201) 487 (–947 to 1920) 0.506
EQ-5D-5L index 1339 0.491 (0.357) 1333 0.505 (0.352) –0.013 (–0.040 to 0.014) 0.330
Survival days 1560 334 (84) 1561 334 (85) 0.19 (–5.75 to 6.13) 0.951
ICERa 2609 (–11,931 to 17,149) 0.725
a Incremental total cost divided by incremental number of survival days.
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FIGURE 6 Cost-effectiveness plane with means centred.
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Chapter 7 Results 5: an updated systematic
review of randomised controlled trials of
fluoxetine in stroke patients
This chapter is reproduced from Mead et al.63 International Journal of Stroke. Copyright © 2019 bySAGE Publications. Reprinted by permission of SAGE Publications, Ltd.
Introduction
A 2012 Cochrane systematic review of SSRIs for stroke recovery25 suggested that SSRIs, including
fluoxetine, reduced disability in stroke patients even if they did not have depression, but poor
methodological quality of the trials probably introduced bias. In general, systematic reviews and meta-
analyses should be updated as soon as there are new studies that might change the conclusions of the
review. Thus, we, in collaboration with many other individuals (see Appendix 3), conducted an updated
meta-analysis focusing specifically on the role of fluoxetine for stroke recovery, rather than on all SSRIs.
We have included the results of the FOCUS trial and any other RCTs completed since the earlier
review.25 We sought to determine whether or not fluoxetine, at any dose, given within the first year after
stroke to patients who did not have to have mood disorders at randomisation, compared with usual care
or placebo, reduced disability and dependency at the end of treatment, reduced neurological deficits and
fatigue, and improved motor function, mood and cognition at the end of treatment and follow-up, with
the same number of or fewer adverse effects. The methods and results of this updated systematic review
have been published63 and are included here to put the FOCUS trial results into context.
Methods
Protocol and registration
We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) to complete
and report this study.We did not register the current review on PROSPERO as we used the same methods
as the 2012 Cochrane review,25 except for (1) including fluoxetine trials only, (2) excluding trials that require
patients to have mood disorders at randomisation, (3) simplifying our sensitivity analyses by excluding
trials at high or unclear risk of bias in at least one domain rather than considering each domain individually,
(4) excluding trials comparing fluoxetine plus another ‘active treatment’ with the ‘active treatment’ and
(5) defining incomplete outcome data reporting as systematic differences in withdrawals between groups
rather than a total of > 5%. These five criteria were agreed prior to study selection and data extraction.
After study selection and data extraction, but prior to analyses, we decided to report the proportion of
participants who were independent (mRS 0–2) rather than the proportion of participants who were
dependent (mRS 3–5).
Random-effects models were used in the 2012 Cochrane review25 because we assumed that the included
studies would represent a random sample of the effect sizes that could be observed. Given that the large
FOCUS trial55 had systematically different results from the smaller trials, a random-effects model would have
given disproportionate weight to smaller studies.64 Therefore, we report fixed-effects models. We undertook
sensitivity analyses using random-effects models and report any major differences between the two.
Eligibility criteria
l Participants: stroke in the previous year. Stroke was defined as sudden-onset focal neurological
disturbance, assumed to be vascular in origin and lasting > 24 hours.65 We excluded trials requiring
patients to have a mood disorder at randomisation.
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
51
l Types of intervention: any dose of fluoxetine, any mode of delivery, given for any duration.
l Comparator group: usual care or a placebo. We excluded studies comparing fluoxetine plus another
‘active treatment’ with ‘active treatment’ alone, because of possible interactions.
l Outcomes: we prespecified two co-primary outcomes – independence or disability at the end of
treatment (using any measure) – rather than the single primary outcome of independence because
changes in disability (performance of activities of daily living) could be of importance to patients
even without a change in overall dependence. Independence (or not) was defined as a dichotomous
variable; we expected to find this commonly reported using the mRS. We anticipated disability being
measured using a number of different continuous outcome measures, which we planned to combine
using standardised mean differences (SMDs).
l Secondary outcomes: independence or disability at the end of follow-up. Neurological score, new
depression during the trial but not based on standardised criteria, anxiety, cognition, quality of life,
fatigue, health-care costs, death, motor scores, adverse events (at the end of treatment and/or at
the end of follow-up), ‘leaving the trial before scheduled follow-up’, which included any reason other
than death for missing outcome data.
l Report characteristics: we included all reports irrespective of year of publication, language and
publication status. Where necessary, we sought unpublished data from authors.
Information sources
Our information sources and search strategy are described in Appendix 2. We screened reference lists
from review articles and included papers. We contacted experts to identify additional studies.
Study selection
Duplicate references were removed using Covidence software (Melbourne, VIC, Australia;
www.covidence.org). Titles and abstracts were scrutinised by two authors. Obviously irrelevant articles
were excluded. Full texts of potentially relevant articles were retrieved and inclusion criteria applied by two
authors. A third author was involved if there was disagreement.We included studies meeting our criteria.
Data collection process
Two reviewers independently extracted data from the new trials using Covidence. We contacted the
authors if data were missing or required in a different format.
Data items
Continuous and dichotomous data were extracted. If trials reported the same number of patients at the
beginning and the end, we assumed that there had been no deaths. If there was no description of how
adverse events were recorded, we included any available data on adverse events, but did not assume the
absence of serious adverse events unless the authors had explicitly reported this. If there was a different
number of patients at the end of the trial, we extracted data on deaths and dropouts for other reasons.
The denominator was the number of patients for whom a particular outcome was available.
Risk of bias of individual studies
Two authors applied the same criteria as previously.25 We included allocation (selection bias), blinding
(performance bias and detection bias), incomplete outcome data (systematic differences between
groups in withdrawals from a study), selective reporting and other potential sources of bias.
Prespecified sensitivity analyses
Sensitivity analyses explored the influence of bias by excluding studies with unclear or high risk of bias
across at least one key domain.64
Summary measures and synthesis of results
Risk ratios (RRs) were used for dichotomous data and for ordinal scales with an established cut-off
point. SMDs were used for continuous data and ordinal scales with no standard cut-off point. We
prespecified our interpretation of SMD: 0.2 represents a small effect, 0.5 represents a moderate effect
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and 0.8 represents a large effect.64 Unpublished data kindly provided by the authors of one trial66
reported medians, IQRs and ranges (Dr Juan Marquez Romero, Mexican Institute of Social Security,
Departmento de Neurologia Aguascalientes, Mexico, 20 September 2018, personal communication.).
We estimated the mean and SD using the best available method.67
Risk of bias across studies
A funnel plot was used to investigate publication bias. When available, we scrutinised protocols to
investigate selective reporting.
Subgroup analyses
Given that fluoxetine may be more effective when given earlier after stroke, we aimed to explore the
influence of time since stroke at recruitment on our primary outcome by categorising studies as
< 3 months, 3 to 6 months, 6 to 9 months and 9 to 12 months since the stroke.
Results
From the database searches, we identified 3412 references, removed 426 duplicates, screened 2988
references and assessed 499 full texts for eligibility (Figure 7). Three published papers had the same
grant number,68–70 very similar inclusion criteria and recruited patients from the same hospital during
overlapping time periods; one appeared to be the 3-year follow-up data70 from one of the earlier
publications.69 Thus, we included the publication with the largest number of patients reporting our
prespecified outcomes69 and categorised the other two68,70 as ‘awaiting assessment’ pending further
information. We identified three further new eligible trials from the database searches66,71,72 and one by
contact with experts.73 We also included the FOCUS trial.55
These six new trials (n = 3710)55,66,69,71–73 were added to seven eligible trials12,16,17,74–78 (n = 435)
identified in the 2012 Cochrane review25 (total of 13 completed trials, n = 4145, Table 31). One further
registered trial was withdrawn because it recruited no patients.79
Several ongoing RCTs together aim to recruit about 3775 patients.
Risk of bias
There were four high-quality trials (n = 3283) with a low risk of bias across important quality
criteria17,55,66,72 (Figure 8). One terminated early having recruited six patients, and reported no deaths.72
Results of studies and synthesis of results
Co-primary outcomes: independence (Figure 9) and disability at end of treatment
(Figure 10)
Three trials (n = 3249) reported independence.17,55,66 Fixed-effects meta-analysis found no difference in
the proportion who were independent (36.6% fluoxetine vs. 36.7% control, RR 1.00, 95% CI 0.91 to
1.09; p = 0.99; I2 = 78%) and no difference in disability (seven trials, n = 3404, SMD 0.05, 95% CI –0.02
to 0.12; p = 0.15; I2 = 81%).
Two other trials73,78 reported improvements in mRS in the fluoxetine group but the data were in a
format that could not be used in the meta-analysis and the authors did not respond to our requests for
clarification.
Random-effects models demonstrated a small but statistically significant benefit of fluoxetine for
disability (SMD 0.34, 95% CI 0.04 to 0.64; p = 0.03; I2 = 81%), and a higher RR (RR 1.87, 95% CI 0.74
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to 4.56; p = 0.19; I2 = 78%) of being independent than the fixed-effects models because of the greater
weight given to smaller positive trials.
Secondary outcomes at the end of treatment: summary effect sizes (Table 32)
Fluoxetine was associated with better neurological scores (eight trials, n = 803, SMD –0.28, 95% CI
–0.42 to –0.14; p < 0.001; I2 = 77%), lower (fewer depressive symptoms) depression scores (six trials,
n = 3113, SMD –0.16, 95% CI –0.23 to –0.09; p < 0.0001; I2 = 92%), fewer diagnoses of depression
(two trials, n = 3194, RR 0.77, 95% CI 0.65 to 0.90; p = 0.001; I2 = 53%) but more seizures (seven trials,
n = 3815, 3.9% vs. 2.6%, RR 1.49, 95% CI 1.05 to 2.11; p = 0.03; I2 = 0). Random-effects models gave
broadly similar results. The FOCUS trial identified a small excess of bone fractures in the fluoxetine
group, which was statistically significant (see Table 13). No other trial reported fractures.
End of follow-up
Two trials (n = 2924) reported disability at the end of follow-up (SMD 0.11, 95% CI –0.17 to 0.40;
p = 0.45; I2 = 85%; fixed effects). Only one trial (FOCUS) reported independence at the end of follow-up;
there was no difference between groups.55
References excluded 
(n  = 480) 
• Duplicate reference, n = 150
• Review; no new trials, n = 117
• Commentaries, n = 68
• Wrong comparator, n = 30
• Wrong study design, n = 29
• Wrong patient population, n = 21 
• Wrong drug, n = 32
• Wrong intervention, n = 13
• Conference proceedings; no
    new trials, n = 6
• Old reviews (2011 or earlier), n = 5
• The trial never started, n = 4
• Follow-up of original trial, n = 2
• Registry database link, n = 1
• Wrong outcomes, n = 1 
• Book; no new studies, n = 1 
Six new studies included (and were
added to the seven
identif ied in the 2012 Cochrane
review)
Studies ongoing 
(n = 10)
Studies awaiting classif ication 
(n = 3)
Study terminated 
(n = 1)
Study
identif ied by
contact with
experts
(n  = 1)
References imported 
for screening 
(n  = 3413)
Duplicates removed
(n  = 426)
Studies screened
(n  = 2988)
Studies irrelevant
(n  = 2489)
Full-text studies assessed 
for eligibility 
(n  = 499)
FIGURE 7 Flow diagram showing selection of studies. Reproduced from Mead et al.63 International Journal of Stroke.
Copyright © 2019 by SAGE Publications. Reprinted by permission of SAGE Publications, Ltd.
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TABLE 31 Characteristics of the RCTs that are included in this review
Study
(first author
and year) Country
Participants
(pathological type and
time since stroke)
Number
recruited
Number
included
at end of
treatment
Dose and
duration of
fluoxetine Control
Outcomes reported
by the trial authors Follow-up period
Birchenall 201972 France Stroke or brain
haemorrhage, day 3 to
day 15
6 (study
terminated
early)
6 20 mg daily for
3 months
Placebo Several clinical and
TMS measurements,
death
End of treatment
and at month 6
Chollet 201117 France Ischaemic stroke,
5–10 days
118 113 20 mg daily for
3 months
Matching placebo Primary outcome:
FMMS. Secondary
endpoints: NIHSS,
mRS and MADRS at
0, 30 and 90 days.
AEs
End of treatment
Dam 199616 Italy Ischaemic stroke,
1–6 months
35 33 20 mg daily for
12 weeks
Matching placebo HDRS, HSS (total, gait
and motor scores), BI,
death, AEs
End of treatment
FOCUS
collaboration
201855
UK Any stroke, 2–15 days 3127 3106 20 mg daily for
6 months
Matching placebo Primary: mRS
Secondary: SIS,
depression, MHI5,
fatigue, EQ-5D-5L,
health care costs
End of treatment
and then 6 months
later
He 200474 China First ever stroke, all
pathological types;
mean time 3.1 days in
fluoxetine and 3.5 days
in control
84 71 20 mg daily for
8 weeks
Usual stroke care HAMD, SSS, AEs End of treatment
He 201669 China Ischaemic stroke,
within 1 week
374 350 20 mg daily for
90 days
Usual care NIHSS, BI, AEs End of treatment
and at day 180
Kong 200775 China Any pathological type,
within 7 days
90 73 20 mg daily for
8 weeks
Matching placebo HAMD, BI, NIHSS
Somatic side effects
and hyponatraemia
End of treatment
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TABLE 31 Characteristics of the RCTs that are included in this review (continued )
Study
(first author
and year) Country
Participants
(pathological type and
time since stroke)
Number
recruited
Number
included
at end of
treatment
Dose and
duration of
fluoxetine Control
Outcomes reported
by the trial authors Follow-up period
Li 200476 China Any pathological type;
mean time to
recruitment was 2 days
67 67 20 mg daily for
4 weeks
Routine stroke
care
HAMD, CSS; AEs in
fluoxetine group
End of treatment
Marquez-Romero
201366
Mexico Intracerebral
haemorrhage within 10
days
32 30 20 mg daily for
90 days
Matching placebo Primary: FMMS, mRS
Secondary: NIHSS, BI,
AEs
End of treatment
Pariente 200112 France Lacunar ischaemic
stroke
8 8 Single 20-mg
dose
Placebo Finger tapping and
clinical scales
presented only as
graphs. fMRI
activation location
Post treatment
Robinson 200077
(follow-up
reported in
Mikami 201178)
USA and
Argentina
All pathological types,
within 6 months
33 28 Dose increased
over 3 weeks
from 10mg to
30 mg daily; total
12 weeks
Matching placebo HDRS, mRS, FIM,
MMSE, JHFI, death,
AEs
End of treatment
Shah 201673 India Haemorrhagic stroke,
5–10 days after onset
89 84 10 mg for 1 week;
increased to
20 mg after
1 week; total
3 months
Inert capsule
‘similar’ to
fluoxetine
Primary outcome:
FMMS
mRS and AEs
End of treatment
Zhao 201171 China Stroke with aphasia,
‘early treatment with
fluoxetine', precise
time not stated
82 71 20 mg daily for
12 weeks
Standard care MESSS, ADL End of treatment
ADL, activities of daily living; AE, adverse event; BI, Barthel Index; CSS, Chinese Stroke Scale; FIM, Functional Independence Measure; FMMS, Fugl-Meyer Motor Scale;
fMRI, functional magnetic resonance imaging; HAMD/HDRS, Hamilton Depression Rating Scale; HSS, Hemispheric Stroke Scale; JHFI, Johns Hopkins Functioning Inventory;
MADRS, Montgomery–Åsberg Depression Rating Scale; MMSE, Mini Mental State Examination; MESSS, Modified Edinburgh-Scandinavian Stroke Scale; SSS, Scandinavian Stroke
Scale; TMS, transmagnetic stimulation.
Reproduced from Mead et al.63 International Journal of Stroke. Copyright © 2019 by SAGE Publications. Reprinted by permission of SAGE Publications, Ltd.
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Sensitivity analyses: high-quality trials at low risk of bias only (Table 33) (fixed effects)
The fixed-effects models found a small but statistically significant effect on depression scores at
the end of treatment (two trials, n = 2861, SMD –0.11, 95% CI –0.19 to –0.04; p = 0.002; I2 = 69%).
Random-effects models found a slightly larger effect size for depression, which was not statistically
significant (SMD –0.23, 95% CI –0.56 to 0.10; p = 0.07; I2 = 61%).
Subgroup analyses
We did not conduct subgroup analyses because all trials except two (n = 68) recruited patients within
3 months of stroke onset.
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FIGURE 8 Risk of bias. +, low risk of bias; ?, unclear risk of bias; –, high risk of bias. Reproduced from Mead et al.63
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Study or subgroup
Fluoxetine
Events EventsTotal Total Weight (%)
Control Risk ratio
M–H, fixed, 95% Cl  Year
Risk ratio
M–H, fixed, 95% Cl
1.2.1 Trials before FOCUS
Chollet 201117
Marquez-Romero 201366
Subtotal (95% Cl)
Total events
Heterogeneity: χ2 = 0.00, df = 1 (p = 0.96); l2 = 0%
Heterogeneity: χ2 = 9.23, df = 2 (p = 0.010); l2 = 78%
Test for subgroup differences: χ2 = 9.04, df = 1 (p = 0.003); l2 = 88.9%
Test for overall effect: z = 0.02 (p = 0.99)
Heterogeneity: not applicable
Test for overall effect: z = 2.96 (p = 0.003)
Test for overall effect: z = 0.59 (p = 0.55)
1.2.2 FOCUS 2018
FOCUS collaboration 201855
Subtotal (95% Cl)
Total events
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Total  (95% Cl)
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8
57
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23
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FIGURE 9 Forest plot: mRS (0–2) at the end of treatment. df, degrees of freedom; M–H, Mantel–Haenszel. Reproduced from Mead et al.63 International Journal of Stroke. Copyright ©
2019 by SAGE Publications. Reprinted by permission of SAGE Publications, Ltd.
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Study or subgroup
Fluoxetine
Mean MeanSD SDTotal Total Weight (%)
Control Standard mean difference Standard mean difference
IV, fixed, 95% Cl IV, fixed, 95% Cl
1.4.1 Trials before FOCUS
Test for subgroup differences: χ2 = 17.68, df = 1 (p < 0.0001); l2 = 94.3%
Heterogeneity: χ2 = 13.56, df = 5 (p = 0.02); l2 = 63%
Heterogeneity: χ2 = 31.24, df = 6 (p < 0.0001); l2 = 81%
Test for overall effect: z = 4.42 (p < 0.00001)
Test for overall effect: z = 1.42 (p = 0.15)
Heterogeneity: not applicable
Test for overall effect: z = 0.42 (p = 0.68)
1.4.2 FOCUS 2018
FOCUS collaboration 201855
Favours control
−1 −0.5 0.50
Favours fluoxetine
1
Dam 199616
Robinson 200077
Kong 200775
Zhao 201171
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He 201669
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0.62 (0.15 to 1.09)
1.11 (0.60 to 1.61)
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FIGURE 10 Forest plot: disability at the end of treatment. df, degrees of freedom. IV, inverse variance. Reproduced from Mead et al.63 International Journal of Stroke. Copyright © 2019
by SAGE Publications. Reprinted by permission of SAGE Publications, Ltd.
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TABLE 32 Effects sizes from meta-analysis of primary and secondary outcomes at the end of treatment, from all trials
using fixed-effects models, where at least two trials provided data that could be included
Outcome
Number of trials
(number of participants)
contributing to the
meta-analysis
Effect size (RR or SMD)
and 95% CI p-value I2
Independent (mRS 0–2) 3 (n = 3249) RR 1.00 (0.91 to 1.09) 0.99 78%
Disability 7 (n = 3404) SMD 0.05 (–0.02 to 0.12) 0.15 81%
Neurological deficit score 8 (n = 803) SMD –0.28 (–0.42 to –0.14) < 0.0001 77%
Depression-continuous data 6 (n = 3113) SMD –0.16 (–0.23 to –0.09) < 0.0001 92%
Depression-dichotomous 2 (n = 3194) RR 0.77 (0.65 to 0.90) 0.001 53%
Motor score 5 (n = 3079) SMD 0.06 (–0.02 to 0.13) 0.12 95%
Cognition 2 (n = 2834) SMD –0.04 (–0.11 to 0.03) 0.32 0%
Death 11 (n = 3824) RR 1.0 (0.79 to 1.26) 1.00 0%
Seizures 7 (n = 3815) RR 1.49 (1.05 to 2.11) 0.03 0%
Gastrointestinal symptoms
(nausea, diarrhoea, abdominal pain)
7 (n = 688) RR 1.38 (0.99 to 1.94) 0.06 8%
Serious bleeding 2 (n = 3477) RR 1.10 (0.72 to 1.62) 0.67 0%
Leaving before the end of first
follow-up
11 (n = 3972) RR 0.92 (0.61 to 1.40) 0.71 0%
RR if < 1.0 indicate fluoxetine better than control. SMD if negative indicates improvement with fluoxetine.
Reproduced from Mead et al.63 International Journal of Stroke. Copyright © 2019 by SAGE Publications. Reprinted by
permission of SAGE Publications, Ltd.
TABLE 33 Summary effect sizes for trials at low risk of bias, at the end of treatment, where at least two trials reported
the outcome of interest (fixed-effects models)
Outcome
Number of trials
and participants
contributing to the
meta-analysis
Effect size (RR or SMD)
and 95% CI p-value I2
Independent (mRS 0–2) 3 (n = 3269) RR 1.00 (0.91 to 1.09) 0.99 78%
Disability 2 (n = 2853) SMD –0.01 (–0.09 to 0.06) 0.75 0%
Neurological deficit score 2 (n = 142) SMD –0.30 (–0.63 to 0.04) 0.08 0%
Depression (continuous data) 2 (n = 2861) SMD –0.11 (–0.19 to –0.04) 0.002 69%
Motor score 3 (n = 2936) SMD 0.02 (–0.05 to 0.09) 0.58 88%
Death 4 (n = 3260) RR 0.99 (0.79 to 1.25) 0.95 0%
Gastrointestinal symptoms 2 (n = 148) RR 2.19 (1.0 to 4.76) 0.05 0%
Leaving the trial before first follow-up 4 (n = 3283) RR 1.01 (0.48 to 2.10) 0.98 0%
Seizures 3 (n = 3275) RR 1.47 (0.99 to 2.18) 0.06 0%
RR if < 1.0 indicate fluoxetine better than control. SMD if negative indicates improvement with fluoxetine.
Reproduced from Mead et al.63 International Journal of Stroke. Copyright © 2019 by SAGE Publications. Reprinted by
permission of SAGE Publications, Ltd.
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Chapter 8 Discussion
In this section, we first discuss the main results of the FOCUS trial,55 and the possible explanationsof why we did not confirm the very encouraging results of the earlier RCTs included in our 2012
systematic review.25 We then discuss the results of our post hoc analyses relating to fractures and,
finally, the results of our updated systematic review, which aims to put the FOCUS trial results into
the context of all completed similar trials.
The FOCUS trial, along with its sister trials in Australasia/Vietnam (AFFINITY) and Sweden (EFFECTS),62
which are ongoing at the time of this report, was established to answer several questions. Our discussion
will first focus on whether or not we have addressed these questions.
Primary question: does the routine, early administration of fluoxetine
(20 mg o.d.) for 6 months after an acute stroke improve patients’
functional outcome?
Our results do not support the hypothesis that a course of fluoxetine improves patients’ outcomes. We
have considerable confidence that this is the correct conclusion because of the trial’s methodological
strengths.
The strengths of the study, supporting the internal validity of the results, are that bias was minimised
by central randomisation without any prospect of foreknowledge; blinding of patients, carers and
outcome assessment (with only three episodes of unblinding); very few losses to follow-up (< 1%);
and published prespecified intention-to-treat analyses. The small difference in the number of patients
stopping the trial medication for perceived adverse effects suggests that unblinding owing to adverse
effects was unlikely to have had a significant effect on our results. In any case, expectation bias would
normally be expected to bias the result in favour of the active treatment. Random error was also
minimised by randomising a large number of patients and high rates of follow-up, providing much
greater statistical power than previous similar trials.
However, it is important to consider whether or not methodological factors could have caused us to
miss an improvement in outcome. Possible explanations might include:
l Inadequate power to detect a small but clinically significant improvement in functional outcome.
Our sample size estimate indicated that we had 90% probability of detecting an effect equivalent to
a COR of 1.23 at the 5% significance level. The planned total sample size for the FOCUS, AFFINITY
and EFFECTS trials,62 6000 patients, provides 90% power to detect a smaller effect size equivalent
to a COR of 1.16. Our estimate of effect in the FOCUS trial was a COR of 0.951 (95% CI 0.839
to 1.079; p = 0.439; these 95% CIs, which include neither 1.16 nor 1.23, make it very unlikely that
we have overlooked a treatment effect of the size that we had considered likely or of clinical
importance).
l Inclusion of the wrong type of stroke patients. For instance, those included in the FLAME trial,17 on
average, had more severe strokes and all had motor deficits. Our prespecified subgroup analyses
(see Table 11) did not identify any interaction between our overall effect and any subgroup. We
specifically explored whether or not there was a benefit for patients who had a motor deficit at
baseline; there was not.
The external validity of the results, at least for the UK stroke population, is supported by the large
number of participating hospitals throughout the UK. Compared with unselected stroke patients
admitted to UK hospitals (Table 34), there were a few differences to the subjects enrolled in the
trial.80,81 The patients enrolled in the FOCUS trial had slightly more severe strokes (NIHSS 6 vs. 4),
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which probably reflected the inclusion criteria that required patients to have a neurological deficit
persisting at the time of enrolment. Also, 60% were male, compared with a UK average of 50%: an
unexplained but common observation in stroke trials.82 Patients enrolled were slightly younger (mean
71.4 years) than unselected patients who were admitted to hospital with stroke in the UK, which
might partly explain the male preponderance, with older women being under-represented. Many of
the studies included in the previously published systematic review of RCTs of fluoxetine were from
China; non-white patients made up < 5% of those recruited in the FOCUS trial. The ongoing AFFINITY
trial is recruiting in Vietnam and will include a much larger proportion of Asian patients.62
The primary outcome measure, the modified Rankin Scale, was too insensitive
Some might criticise our use of the mRS, and specifically the smRSq, because it is too simple and not a
directly observed assessment of function, but is patient or proxy reported. However, the smRSq is a
valid, reliable measure of functional outcome, which is patient centred, thus ensuring that our results
are relevant for patients and their families.18,35–37 We cannot definitely exclude an effect of fluoxetine
on a directly measured neurological deficit, such as the Fugl-Meyer Motor Score, which was measured
in the FLAME trial.17 A structured neurological examination during follow-up would have been impractical
TABLE 34 Baseline characteristics at randomisation and comparison with characteristics of unselected stroke admissions
in UK national audits: Sentinel Stroke National Audit Programme 2013–1480 and Scottish Stroke Care Audit 201781
Characteristics of patients randomised
Allocated treatment
Comparative data from UK
national audits
Fluoxetine Placebo
Sentinel Stroke
National Audit
Programme
(N= 74,307)
Scottish Stroke
Care Audit
(N= 9345)
All patients, n (%) 1564 (100.00) 1563 (100.00)
Female, n (%) 589 (37.66) 616 (39.41) 50% 49%
Male, n (%) 975 (62.34) 947 (60.59) 50% 51%
Age (years), mean (SD) 71.24 (12.35) 71.48 (12.06) 77 73
Lives alone, n (%) 485 (31.01) 516 (33.01) 38%
Independent before stroke, n (%) 1431 (91.50) 1435 (91.81) 81% 82%
Past history, n (%)
Prior ischaemic stroke/TIA 274 (17.52) 294 (18.81) 27%
Known diabetes 337 (21.55) 303 (19.39) 19%
Stroke type, n (%)
Ischaemic stroke 1410 (90.15) 1406 (89.96) 88% 87%
Intracerebral haemorrhage 154 (9.85) 157 (10.04) 11% 13%
Stroke severity
Able to walk at enrolment, n (%) 435 (27.81) 412 (26.36) 48%
Able to lift both arms off bed, n (%) 924 (59.08) 935 (59.82) 63%
Able to talk and not confused, n (%) 1166 (74.55) 1164 (74.47) 66%
NIHSS, median (IQR) 6 (3–11) 6 (3–11) 4 (2–10)
Enrolled as a hospital inpatient, n (%) 1544 (98.72) 1536 (98.27) 100%
Reproduced from the FOCUS trial collaboration.55 © 2018 The Author(s). Published by Elsevier Ltd. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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to include in this large pragmatic multicentre trial. In addition, local face-to-face assessments of outcomes
are likely to be more prone to unblinding owing to patients reporting adverse effects of trial medication
to those assessing outcome, than would occur through postal and telephone follow-up. However, we have
shown that even if fluoxetine improves neurological deficits, a resulting improvement in functional status
measured with the mRS or SIS is unlikely.
Non-adherence might have diluted any benefit
The main limitation of the FOCUS trial was the degree of non-adherence to the trial medication,
which might have led us to underestimate any treatment effect. However, adherence measured in the
FOCUS trial was superior to that reported in routine clinical practice and not very different between
the treatment groups in the trial.83 Where reduced adherence resulted from patients experiencing
possible adverse reactions or a perceived change (or lack of change) in their condition, then this might
be more likely to differ between the fluoxetine and placebo groups. We repeated the analysis of our
primary outcome, having sequentially excluded patients with different reasons for, and different
degrees of, adherence. Such per-protocol analyses may increase the risk of bias, usually in favour of
the active treatment. Our analyses (see Table 12) did not show any trend towards greater benefit from
fluoxetine in those with greater adherence.
Excess of fractures may have offset the functional benefits
Removing the 65 patients with one or more fractures during follow-up from the primary analysis
(ordinal analysis of the mRS) did not significantly alter the estimate of effect of fluoxetine on mRS
(COR including those with fractures 0.951, 95% CI 0.839 to 1.079; p = 0.439; COR for those without
fractures 0.961, 95% CI 0.847 to 1.093; p = 0.545).
Patients recruited received lower background rehabilitation intensity than in FLAME
The proponents of fluoxetine as a medication that helps functional recovery claim that it amplifies the
effects of physical therapy by enhancing neuroplasticity.17 We had no measure of the intensity of
rehabilitation or delivery of physical therapies during follow-up. This is likely to have varied considerably
between centres and patients. Our results are very likely to apply to the effects of fluoxetine in patients
admitted to UK hospitals with a stroke. The EFFECTS trial is being carried out in Sweden where the
impression is that patients receive higher doses of physiotherapy and other physical rehabilitation than
in the UK. The EFFECTS trial is also estimating the intensity of physiotherapy treatment. The planned
individual patient data meta-analysis will be able to determine if there are differences in the effect of
fluoxetine on functional outcome between the UK and Sweden, and perhaps explore any interaction
with intensity of physiotherapy.
Secondary questions
If fluoxetine improves functional outcome, does any improvement persist after treatment
is stopped?
We demonstrated no effect at 6 months, and the data at 12 months do not suggest any improvement
in any measure of functional outcome in the fluoxetine group compared with the placebo group.
Does the routine early administration of fluoxetine after acute stroke causing motor
impairment improve patients’ motor function and does any improvement persist after
treatment is stopped?
There was no evidence of benefit from fluoxetine on motor outcomes (as defined by relevant domains
of the SIS) at 6 or 12 months in those patients with motor dysfunction at baseline based on the NIHSS.
Similarly, in those with communication difficulties at baseline, there was no evidence of benefit from
fluoxetine on the communication domain of the SIS at 6 or 12 months in those patients with
communication dysfunction at baseline based on the NIHSS.
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In those patients with impairments that preclude the formal assessment of post-stroke
mood, does fluoxetine improve outcomes?
A prespecified subgroup analysis did not indicate any interaction between the patients’ ability or not to
have their mood assessed at baseline and a treatment effect (see Table 11).
Does fluoxetine improve patients’ outcome with respect to mood, fatigue, cognition,
health-related quality of life or participation and does any improvement persist after
treatment is stopped?
The only improvement in patients’ outcome at 6 months was a small improvement in mood, measured
with the MHI-5 (see Table 15). This was consistent with our observation that new episodes of depression
were less commonly diagnosed and thus treated within the first 6 months in the group allocated
fluoxetine (see Table 13). The difference in MHI-5 between groups and the difference in rates of new
depression by 12 months were no longer statistically significant (see Tables 19 and 20). No other
secondary measure of outcome was significantly improved.
A previous systematic review included five RCTs, including FLAME,17 in non-depressed stroke patients,
which tested whether or not SSRIs (two fluoxetine, two sertraline and one escitalopram) prevented the
development of post-stroke depression.84 In a pooled analysis, 23 out of 248 (9.3%) patients treated
with a SSRI developed post-stroke depression, compared with 59 out of 242 (24.4%) patients treated
with a placebo; the authors reported an OR of 0.37 (95% CI 0.22 to 0.61; p = 0.001).84 The rate of
depression in the placebo arms of these trials was much higher than that in the FOCUS trial, which
may have reflected the characteristics of the patients, who tended to have had more severe strokes
than those in the FOCUS trial, or perhaps different methods of diagnosing depression. This is
consistent with our findings in the direction, if not the magnitude, of the treatment effect.
Does fluoxetine reduce the cost of health care over the first year?
No; there was no evidence from our health economic analyses that fluoxetine was associated with a
reduced cost of health care over the first year (see Tables 25 and 26).
Does fluoxetine increase the risk of serious adverse events?
Our data showed a statistically significant increase in the risk of bone fractures in the group allocated
fluoxetine. The observed 1.4% absolute excess of bone fractures at 6 months with fluoxetine in the
FOCUS trial is consistent with previous reports from large case–control and cohort studies.28–30
The size of the increased risk in the previous observational studies tended to be greater than in
the FOCUS trial, but this might be attributable to the inherent confounding by treatment indication
in observational studies.
The rates of other serious adverse reactions referred to in the SmPC of fluoxetine, which we included
as secondary outcomes in this trial (e.g. epileptic seizures, falls, hyponatraemia, uncontrolled diabetes
and upper gastrointestinal bleeding), were higher in the fluoxetine group than in the placebo group, but
the absolute differences were small and were not statistically significant (see Table 13). It seems likely
that there is an excess of these recognised adverse effects, but we had an insufficient number of
patients to confirm this reliably. Despite concerns about fluoxetine’s effect on platelet function and
interactions with antiplatelet and anticoagulant medications, we observed no effect on bleeding or
thrombotic adverse events (see Table 14). The trial was not powered to detect increases in these
recognised adverse effects of fluoxetine.
The AFFINITY and EFFECTS trials, which are of similar design to the FOCUS trial, but with smaller
recruitment targets, are in progress.62 These should allow us to confirm the effects on post-stroke
depression and bone fractures and provide more precise estimates of the benefits and harms of early
fluoxetine to guide its use in stroke patients and perhaps other elderly people with comorbidities.
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Summary
In summary, the FOCUS trial has shown that 20 mg of fluoxetine started early and given daily for
6 months after an acute stroke did not influence patients’ functional outcome, but did decrease the
occurrence of depression and increase bone fractures. These results do not support the routine use of
fluoxetine for the prevention of post-stroke depression or to promote recovery of function. Ongoing
trials and a planned individual patient data meta-analysis are needed to confirm or refute a modest
benefit of fluoxetine for functional outcome, either overall or in particular subgroups, and to provide
more precise estimates of any harms.
Discussion of the post hoc analyses relating to fractures occurring during
the 6-month treatment period
The most common site of fractures among patients with stroke enrolled in the FOCUS trial and
assigned fluoxetine or placebo for 6 months was the neck of femur, and most fractures were in sites
associated with osteoporosis; almost all resulted from a fall. Greater age, female sex and allocation to
fluoxetine were independent predictors of subsequent fractures. An increased risk of falling is likely to
explain much of the excess risk of fractures because most fractures were associated with a fall. Falls
with injury were more common in the fluoxetine group than in the placebo group [n = 120 (7.67%) vs.
n = 94 (6.01%); p = 0.0663], although the difference did not quite reach statistical significance and the
risks in the two treatment groups diverged early after randomisation. No other baseline factors
analysed had statistically significant associations with fracture risk.
These findings in an adequately powered prospective randomised trial confirm that the association
between SSRI and fracture risk noted in observational studies is real and is not due to methodological
biases, and that SSRI medication is likely to be causative. Our finding that greater age and female sex
are associated with a greater fracture risk confirms the findings of previous observation studies in
stroke.28–30 The risk of fractures appears to increase soon after randomisation (see Figure 5) and most
fractures were related to falls (see Table 21), suggesting that the predominant mechanism explaining the
excess of fractures is likely to be the non-significant excess of falls seen in the FOCUS trial compared
with the control group (see Table 13). This might be due to effects on cognition, co-ordination, balance
or activity levels. However, we cannot exclude a contribution from fluoxetine’s possible effect on
bone density.
These predefined secondary analyses have several limitations. The number of fractures in the first
6 months was modest, which means that we were only able to identify powerful predictors of fracture
risk. Our only baseline indicators of bone density were previous fractures and the use of medications to
reduce bone density loss at baseline. We had no direct measures of bone density. In addition, the effect
of fluoxetine, and other medications, may have been diluted by non-adherence or changes to medication
after randomisation. We did not collect data on current medication at the time of the fracture. Also, we
did not systematically collect fractures beyond 6 months so cannot determine whether or not the effect
of fluoxetine on fracture risk persists, as it might if it causes osteoporosis, or whether or not the risk
subsides after stopping if it caused falls by affecting balance, etc., or increased activity by reducing
depression. We did not systematically collect data on the side of the fracture so we could not reliably
confirm previous findings that fractures most often affect the side of any weakness.30
The cost-effectiveness of fluoxetine
There was no evidence that fluoxetine improves health outcomes, and it did not have a significant
effect on the costs of health care, even though it reduced the frequency of new depression and
increased the risk of fractures. Treatment with fluoxetine is cheap, but treatment is not justified by the
clinical or economic outcomes.
DOI: 10.3310/hta24220 Health Technology Assessment 2020 Vol. 24 No. 22
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
65
The FOCUS results in the context of all similar randomised controlled trials
The updated systematic review of fluoxetine for stroke recovery identified 13 trials that recruited
> 4000 patients, of which four trials (n = 3283) were of high methodological quality.
There were no differences between groups for the co-primary outcomes of dependency and disability.
Fluoxetine was associated with better neurological scores at the end of treatment, lower depression
scores (fewer symptoms of depression) and fewer diagnoses of depression, although the effect sizes
were all small and there was substantial heterogeneity. There was a higher risk of seizures with
fluoxetine. However, when only high-quality trials were considered, the only statistically significant
difference between groups was lower depression scores (fewer symptoms) at the end of treatment.
We used fixed-effects models as these give appropriate weight to larger trials. The sensitivity analysis
using random-effects models found a large benefit of fluoxetine on independence (RR 1.87) because of
the disproportionate weight given to smaller trials. Fixed- and random-effects models produced only
slightly different effect sizes for depression scores.
Previous meta-analyses suggested that fluoxetine might reduce dependency and disability if given early
after stroke.24,25,85 This meta-analysis, which includes many more patients than previous reviews, has
not confirmed these promising effects. Although one of the reviews85 strongly recommended fluoxetine
to promote neurological recovery, this recommendation was based on the results of just four
reports,17,68,74,75 only one of which was high quality.17
Thus, these data do not support the routine prescription of fluoxetine early after stroke in order to
reduce dependency and disability. Clinicians and patients may wish to consider the routine use of
fluoxetine early after stroke for its small effects on reducing the incidence of new depression, but this
would need to be weighed up against the excess of seizures and bone fractures. The most important
depression-related outcome after stroke is suicide, which is about double what it is in the non-stroke
population; however, it is rare, and for that reason the RCTs shed no light on whether or not
antidepressant treatment reduces the risk.
There are some limitations at the study and outcome level: only four trials were of high methodological
quality, and not all had been registered prospectively or they reported the same outcomes. Furthermore,
different scales were used for the same outcome; although we used SMD to combine data, the
interpretation of SMD is not intuitive, and clinicians prefer to know the effect size on a familiar scale
(e.g. Functional Independence Measure). Two large ongoing trials (AFFINITY and EFFECTS62) are using
the same measures as those used in the FOCUS trial. A future meta-analysis will report mean
differences for continuous data.
We did not register the review in PROSPERO, but we used almost the same methods as the 2012
Cochrane review, which had a prospectively published protocol.25 We used sensitive searches developed
by Cochrane Stroke,86 and there was complete retrieval of identified research, no language restrictions
and inclusion of unpublished data.
About three-quarters of the patients were from the FOCUS trial. There was quite marked heterogeneity,
even for the high-quality trials (see Table 33); this might be explained by the different types of patients
and health-care settings. Five of the low-quality trials were from China; the three reporting disability all
found favourable effects of fluoxetine. As the evidence base increases, it may be possible to undertake
meta-regression analyses to determine the factors (e.g. country, health-care setting and trial quality)
associated with good outcome.
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Conclusions
The results of the FOCUS trial show that, in the context of the UK NHS, routine use of fluoxetine does
not improve functional outcomes in patients with a recent stroke. There was evidence that its use
reduces the risk of developing new episodes of depression after stroke, but that this is at the expense
of an increased risk of adverse effects, including bone fractures.
Ongoing trials (AFFINITY and EFFECTS62), which used almost identical methods to those of the FOCUS
trial, and the investigators with whom we have closely collaborated, will report in 2020. An individual
patient data meta-analysis including data from FOCUS, AFFINITY and EFFECTS is planned. This will
indicate whether or not the findings of the FOCUS trial are generalisable to other countries, ethnic
groups and health-care systems. They will also help to provide more precise, and generalisable,
estimates of the risks associated with several months of fluoxetine treatment in a predominantly
elderly population. Such data are likely to be relevant to the use of fluoxetine, and perhaps other
SSRIs, in similar populations (i.e. elderly patients with comorbidities). This knowledge could be of
use when counselling patients about the pros and cons of starting treatment with fluoxetine.
Most previous RCTs of fluoxetine, and other SSRIs, have been carried out in patients with depression,
who are often much younger than those recruited into stroke trials, and have only tested short courses
with the purpose of demonstrating an improvement in mood.87 There is a good case for studying the
effects of prolonged courses of fluoxetine, not just those on mood, in older patients who are likely to
be more susceptible to adverse effects. Such information would be useful in balancing the risks against
the perceived benefits of using SSRIs for a variety of indications.
In advance of the FOCUS trial results becoming available, we carried out systematic reviews to
determine whether or not SSRIs might be of benefit in conditions other than stroke through the
same mechanisms that we thought might underpin the hypothesised benefit in stroke. All the reviews
suggested promising effects of SSRIs.88–90 However, before embarking on large trials in these other
conditions, the relevance of the neutral results of the FOCUS trial needs to be considered carefully.
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G Healey, M Crofts, A Chakrabarti, C Hmu, J Keshet-Price, G Ravenhill, C Grimmer, T Soe, I Potter,
P Tam, M Langley]; Aberdeen Royal Infirmary, Aberdeen [20] [M MacLeod (PI), P Cooper, M Christie,
J Irvine, A Joyson, F Annison, D Christie, C Meneses, A Johnson, S Nelson, V Taylor, J Furnace, H Gow,
J Reid, R Clarke]; East Surrey Hospital, Redhill [19] [Y Abousleiman (PI), S Bloom, S Goshawk, J Purcell,
T Beadling, S Collins, S Jones, S Sangaralingham, E Munuswamy Vaiyapuri, M Landicho, Y Begum,
S Mutton, J Allen, J Lowe, M Hughes]; The Royal Victoria Hospital, Belfast [19] [I Wiggam (PI), S Tauro,
S Cuddy, B Wells]; Derriford Hospital, Plymouth [17] [A Mohd Nor (PI), C Eglinton, N Persad, M Kalita,
M Weinling, S Weatherby, D Lashley, A Pace, C Brown, A Mucha, A Shah, J Baker, M Marner,
J Westcott, N Wilmshurst, R Cowan, D Waugh]; Doncaster Royal Infirmary, Doncaster [17] [D Chadha
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(PI), M Fairweather, D Walstow, R Fong]; Morriston Hospital, Swansea [17] [M Krishnan (PI),
H Thompson Jones, C Lynda, C Hughes, C Clements, R Williams, T Anjum, S Storton, D Lynne, L Thomas,
S Tucker, D Colwill, P Jones]; The Hillingdon Hospital NHS Foundation Trust, Uxbridge [17] [E Vasileiadis
(PI), A Parry, C Mason, M Holden, K Petrides, T Nishiyama, H Mehta, S Mumani]; Perth Royal Infirmary,
Perth [16] [S Johnston (PI), C Almadenboyle, S Carson, S Ross, P Nair, M Stirling, E Tenbruck];
James Cook University Hospital, Cleveland [15] [D Broughton (PI), A Annamalai, J Wong, D Tryambake,
L Dixon, A Skotnicka, J Thompson, A Sigsworth, S Whitehouse, J Pagan]; Lister Hospital, Stevenage [15]
[A Pusalkar (PI), H Beadle, K Chan, P Dangri, A Asokanathan, A Rana, S Gohil, K Crabtree, A Cook,
M Massyn, P Aruldoss, S Dabbagh]; Salisbury District Hospital, Salisbury [15] [T Black (PI), C Clarke,
R Fennelly, L Nardone, V DiMartino, A Anthony, D Mead, M Tribbeck]; St Peter’s Hospital, Chertsey [14]
[B Affley (PI), C Sunderland, E Young, L Goldenberg, A Khan, P Wilkinson, L Abbott, R Nari, S Lock,
J Stewart, A Shakhon, R Pereira, M DSouza, S Dunn, N Cron, A Mckenna]; Colchester General Hospital,
Colchester [13] [R Sivakumar (PI), S Cook, A Wright, J Ngeh, R Saksena, J Ketley-O’Donel, R Needle,
E Chinery]; University College London Hospitals NHS Foundation Trust, London [13] [R Greenwood (PI),
L Howaniec, C Watchurst, K Patel, R Erande, M Brezitski, N Passeron, E Elliott, N Oji, D Austin,
A Banaras, C Hogan, T Corbett, R Shah]; Warrington Hospital, Warrington [13] [M Kidd (PI), G Hull,
J Simpson, S Punekar, J Nevinson, H Penney, J Ward, W Wareing, N Hayes, K Bunworth, L Connell,
K Mahawish, G Drummond]; Worthing Hospital, Worthing [13] [N Sengupta (PI), M Metiu, C Gonzalez,
J Margalef, S Funnell, G Peters, I Chadbourn]; Dorset County Hospital, Dorchester [12] [H Proeschel
(PI), P Ashcroft, S Sharpe, S Jones, P Cook, D Jenkinson, D Kelly, H Bray]; Queen Elizabeth The Queen
Mother Hospital, Margate [12] [G Gunathilagan (PI), K Griffiths, K Mears, A Gillian, S Jones, S Tilbey,
S Abubakar, E Beranova]; King’s Mill Hospital, Mansfield [11] [M Cooper (PI), A Rajapakse, A Nasar,
J Janbieh, L Wade, L Otter, I Wynter, S Haigh, R Boulton, J Burgoyne, A Boulton]; Stepping Hill Hospital,
Stockport [11] [J Vassallo (PI), A Hasan, L Orrell, A Khan, S Qamar, S Graham, D Leonard, E Hewitt,
M Haque, J Awolesi, E Bradshaw, A Kent]; Bronglais General Hospital, Aberystwyth [10] [P Jones (PI),
C Duggan, A Hynes, E Nurse, S Raza, U Pallikona, B Edwards, G Morgan, H Tench, R Loosley, K Dennett,
T Trugeon-Smith, R Jones, S Jones, R Williams, D Robson]; Hull Royal Infirmary, Hull [10] [R Rayessa
(PI), A Abdul-Hamid, V Lowthorpe, K Mitchelson, E Clarkson, H Rhian, A Fleming]; Broomfield
Hospital, Chelmsford [9] [R Kirthivasan (PI), J Topliffe, R Keskeys, S Williams, F McNeela, E Bohannan,
L Cooper, S Shah, G Zachariah, F Cairns, T James, L Fergey, S Smolen, A Lyle, E Cannon, S Omer];
Whiston Hospital, Prescot [9] [S Mavinamane (PI), S Meenakshisundaram, L Ranga, J Bate, A Hill,
M Hargreaves, T Smith, S Dealing, L Harrison]; Frimley Park Hospital, Frimley [8] [S Amlani (PI), G Gulli,
M Hawkes-Blackburn, N Hunter, S Levy, L Francis, S Holland, A Peacocke, J Amero, M Burova, O Speirs];
Harrogate Hospital, Harrogate [7] [S Brotheridge (PI), S Al Hussayni, H Lyon, C Hare, S Jackson,
L Stephenson, J Featherstone, A Bwalya]; Royal Blackburn Hospital, Blackburn [7] [A Singh (PI),
M Goorah, J Walford, A Bell, C Kelly, D Rusk, D Sutton, F Patel, S Duberley, K Hayes, L Hunt];
Scarborough Hospital, Scarborough [7] [E Ahmed El Nour (PI), S Dyer, L Brown, K Elliott, E Temlett,
J Paterson, P Wood, M Haritakis, S Honour, C Box, P Cottrell, J Westmoreland, S Young, R Furness];
West Cumberland Hospital, Whitehaven [7] [E Orugun (PI) (deceased), H Crowther, R Glover, C Brewer,
S Thornthwaite]; Macclesfield District General Hospital, Macclesfield [6] [M Sein (PI), K Haque, L Bailey,
S Wong, E Gibson, K Burton, L Brookes, K Rotchell, K Waltho, C Lindley, A Murray, D Leonard,
M Holland]; Royal Lancaster Infirmary, Lancaster [6] [P Kumar (PI), M Khan, P Harlekar, C Culmsee,
L Booth, J Drew, J Ritchie, N Mackenzie, C Thomas, J Barker]; Weston General Hospital, Weston Super
Mare [6] [M Haley (PI), D Cotterill, L Lane, D Simmons, R Warinton, G Saunders, H Dymond, S Kidd,
C Little, Y Neves-Silva]; Basildon and Thurrock University Hospital, Basildon [5] [B Nevajda (PI),
M Villaruel, S Patel, U Umasankar, A Man, N Gadi, N Christmas, R Ladner, R Rangasamy, G Butt,
W Alvares]; Ulster Hospital, Belfast [5] [M Power (PI), S Hagan, K Dynan, D Wilson, S Crothers,
C Leonard, B Wroath, G Douris]; Antrim Area Hospital, Antrim [4] [D Vahidassr (PI), B Gallen,
S McKenna, A Thompson, C Edwards, C McGoldrick, M Bhattad]; Epsom General Hospital,
Epsom [3] [J Putteril (PI), R Gallifent, E Makanju, M Lepore, C McRedmond, L Arundell, A Goulding];
Fairfield General Hospital, Bury [3] [K Kawafi (PI), P Jacob, L Turner, N Saravanan, L Johnson, D Morse,
R Namushi, S Humphrey, R Patel, J McLaughlin]; Leighton Hospital, Crewe [3] [M Salehin (PI), S Tinsley,
T Jones, D Bailey, L Garcia-Alen, L Kalathil, R Miller, N Gautam, J Horton, J Meir, E Margerum,
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A Ritchings, A Jones, K Amor]; Royal Free Hospital, London [3] [V Nadarajan (PI), J Laurence, S Fung Lo,
S Melander, P Nicholas, E Woodford, G McKenzie, V Le, J Crause]; St Helier Hospital, Carshalton [3]
[P OMahony (PI), C Orefo, C McDonald, V Jones, E Osikominu, T Khan, G Appiatse, E Makanju,
A Wardale, M Augustin, H Stone]; North Middlesex University Hospital NHS Trust, London [2] [R Luder
(PI), M Bhargava, G Bhome, V Johnson, R Shah, D Chesser, H Bridger, E Murali]; South Tyneside
General Hospital, South Shields [2] [J Scott (PI), S Morrison, A Burns, J Graham, M Duffy]; Princess
Royal Hospital, Haywards Heath [1] [K Ali (PI), T Sargent, E Pitcher, J Gaylard, J Newman]; Rotherham
Hospital, Rotherham [1] [S Punnoose (PI), M Khan, S Oakley, V Murray, C Bent, R Walker, K Purohit,
A Rees, M Davy, S Besley, O Chohan]; Royal London Hospital (Barts Health), London [1] [L Argandona
(PI), L Cuenoud, H Hassan, E Erumere, A OCallaghan, L Howaniec, O Redjep, G Auld, P Gompertz,
A Song, R Hungwe, H Kabash, T Tarkas]; and Royal Surrey County Hospital, Guildford [1] [A Blight (PI),
S Jones, G Livingstone, F Butler, S Bradfield, L Gordon, J Schmit, A Wijewardane, C Medcalf, T Edmunds,
R Wills, C Peixoto].
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Appendix 2 Development of easy-access
versions of patient information and
consent forms by Professor Marian Brady,
Research Group Lead for Living with
Stroke, Glasgow Caledonian University
Aim
Development of accessible versions of participant information sheets and consent forms for the
FOCUS trial.
Methods
Initial drafts of accessible versions of the standard FOCUS information sheets and consent forms were
prepared for review by people with aphasia based on established methodologies91,92 and sound ethical
principles93 by an experienced speech and language therapist and stroke rehabilitation researcher
(Marian Brady).
Accessible versions of the standard materials were drafted:
l participant information sheets
l participant consent forms.
Two meetings were planned with Speakeasy (Bury, UK) members in Dundee on 28 October and again
on 4 November 2011. Version 1 of the accessible materials were sent in advance of the first meeting to
members of the Speakeasy group (peer support group for people with aphasia following stroke) based
in Dundee. These were sent in advance to provide sufficient time for the Speakeasy members with
language impairment to review and prepare in advance of the first meeting. The process of drafting
and review with comments was scheduled to continue to contribute to the iterative development of
accessible materials until the Speakeasy group felt that they were suitable to be used in the trial with
people with aphasia.
Results
The members reviewed version 1 of the proposed accessible materials in advance of the meeting. Eight
members attended. The materials were reviewed on a statement-by-statement basis with reference
(where necessary) to the standard materials. In this way, we ensured that the essence of the statement
contained in the standard format was retained in the accessible version, and made comments.
Version 2 of the accessible materials was prepared in response to the group’s comments. Version 2
was reviewed by the FOCUS trial team at the University of Edinburgh, including the PIs, trial manager
and other trial staff. They raised some feasibility issues regarding the version 2, which was in colour
and on A4 sheets. They queried whether printing the accessible versions in black and white
(considerably cheaper than the colour) would be acceptable to the group and to people with aphasia.
They also highlighted that printing in black and white would allow sites to easily photocopy the
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materials, which would support implementation of the trial at sites. They also asked whether or not the
A4 size of the materials could be reduced to an A5 booklet, again to support implementation.
Version 3 of the materials was shared with the Speakeasy group (black and white and A5 version),
with a specific response requested in relation to the above issues via the post to members who had
participated in the first meeting. The Speakeasy members responded that although colour printing
would be preferable, for cost reasons the black-and-white versions were acceptable. They also felt that
although larger A4 was preferable, the A5 version would also be acceptable. All other changes were
accepted, and no further changes were requested. A second scheduled face-to-face meeting was
agreed to be unnecessary and was cancelled.
The ethics committee responded positively to the accessible versions of information sheets and consent
forms and agreed that accessible versions could be made available to all potential trial participants as
deemed required by trial staff. The ethics committee’s response to the materials was fed back to the
Speakeasy members.
Discussion and conclusions
In addition, and beyond the FOCUS trial, the accessible materials used in this trial contributed to the
NIHR template materials supporting the involvement of people with aphasia in stroke research.94
Reflections/critical perspective
Involvement of people with aphasia supported the development of accessible materials to support the
ethical inclusion of people with aphasia in the FOCUS trial. The perspective of people with a language
impairment is vital to the development of such materials as it is not possible for people with intact
language skills to perceive all the challenges experienced with a language impairment.
Preparation of accessible versions of materials in stroke research is increasingly standard practice (Big
CACTUS95 and ICONS II96). There is some suggestion that reliance on proxy consent may contribute to
selection bias in the participant recruitment.97
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Appendix 3 Contributors to the updated
systematic review, search strategy and
references
Contributors to updated systematic review
Gillian E Mead, MD, Fellow of Royal College of Physicians of Edinburgh, Professor of Stroke and
Elderly Care Medicine, University of Edinburgh, Edinburgh, UK.
Lynn Legg, Doctor of Philosophy (PhD), Senior Researcher, Department of Medicine for the Elderly,
Royal Alexandra Hospital, Paisley, UK.
Russel Tilney, Doctor of medicine (MD), Department of Medicine, Mater Dei Hospital, Malta.
Cheng Fang Hsieh, MD, Division of Geriatrics and Gerontology, Department of Internal Medicine and
Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Simiao Wu, MD, PhD, Department of Neurology, West China Hospital, Sichuan University, Chengdu,
China.
Erik Lundström, Associate Professor of Neurology, Karolinska Institutet, Department of Clinical
Neuroscience; and Adjunct Senior Lecturer at Department of Neuroscience, Neurology, Uppsala
University, Uppsala, Sweden.
Ann Sofie Rudberg, MD, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,
Sweden.
Mansur Kutlubaev, MD, PhD, Department of Neurology, G.G. Kuvatov Republican Clinical Hospital;
Department of Neurology, Bashkir State Medical University, Ufa, Russia.
Martin S Dennis, Professor of Stroke Medicine, University of Edinburgh, Edinburgh, UK.
Babak Soleimani, MB, Bachelor of Medicine and Bachelor of Surgery, Clinical Fellow, NHS Lothian, UK.
Amanda Barugh, PhD, Consultant Stroke Physician, NHS Lothian, UK.
Maree L Hackett, PhD, Programme Head Mental Health, Associate Professor, Faculty of Medicine,
University of New South Wales, Sydney; Professor of Epidemiology, The University of Central
Lancashire, UK; The George Institute for Global Health, Australia.
Graeme J Hankey, MD, Fellow of the Royal Australasian College of Physicians, Professor of Neurology,
Medical School, The University of Western Australia, WA, Australia.
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Search strategy for updated systematic review
The following searches were carried out (Cochrane Stroke Group Trials Register; date searched:
17 July 2018):
l Cochrane Central Register of Controlled Trials (CENTRAL) (via The Cochrane Library) (date range
searched: 2018, issue 6).
l MEDLINE (via Ovid) (date range searched: 1948 to 17 July 2018).
l EMBASE (via Ovid) (date range searched: 1980 to 17 July 2018).
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost) (date range
searched: 1982 to 17 July 2018).
l Allied and Complementary Medicine (AMED) (via Ovid) (date range searched: 1985 to 17 July 2018)
l PsycINFO (via Ovid) (date range searched: 1967 to 17 July 2018).
l US National Institutes of Health Ongoing Trials Register [via ClinicalTrials.gov (www.clinicaltrials.gov)].
l World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch)
(date searched: 26 June 2018).
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Cochrane Central Register of Controlled Trials (CENTRAL) (via The Cochrane Library)
(2018, issue 6) search strategy
#1. MeSH descriptor Cerebrovascular Disorders explode all trees
#2. (stroke in Title, Abstract or Keywords or poststroke in Title, Abstract or Keywords or post-
stroke in Title, Abstract or Keywords or cerebrovasc* in Title, Abstract or Keywords or (brain in
Title, Abstract or Keywords and vasc* in Title, Abstract or Keywords) or (cerebral in Title, Abstract
or Keywords and vasc* in Title, Abstract or Keywords) or cva* in Title, Abstract or Keywords or
apoplex* in Title, Abstract or Keywords or SAH in Title, Abstract or Keywords)
#3. ((brain* in Title, Abstract or Keywords or cerebr* in Title, Abstract or Keywords or cerebell* in
Title, Abstract or Keywords or intracran* in Title, Abstract or Keywords or intracerebral in Title,
Abstract or Keywords) and (ischemi* in Title, Abstract or Keywords or ischaemi* in Title, Abstract or
Keywords or infarct* in Title, Abstract or Keywords or thrombo* in Title, Abstract or Keywords or
emboli* in Title, Abstract or Keywords or occlus* in Title, Abstract or Keywords))
#4. ((brain* in Title, Abstract or Keywords or cerebr* in Title, Abstract or Keywords or cerebell* in
Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords or intracranial in Title,
Abstract or Keywords or subarachnoid in Title, Abstract or Keywords) and (haemorrhage* in Title,
Abstract or Keywords or hemorrhage* in Title, Abstract or Keywords or haematoma* in Title,
Abstract or Keywords or hematoma* in Title, Abstract or Keywords or bleed* in Title, Abstract
or Keywords))
#5. MeSH descriptor hemiplegia this term only
#6. MeSH descriptor paresis explode all trees
#7. MeSH descriptor Gait Disorders, Neurologic explode all trees
#8. (hemipleg* in Title, Abstract or Keywords or hemipar* in Title, Abstract or Keywords or paresis
in Title, Abstract or Keywords or paretic in Title, Abstract or Keywords)
#9. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10. MeSH descriptor Serotonin Uptake Inhibitors explode all trees
#11. (serotonin in Title, Abstract or Keywords or 5-HT in Title, Abstract or Keywords or “5 HT” in
Title, Abstract or Keywords or 5-hydroxytryptamine in Title, Abstract or Keywords or “5
hydroxytryptamine” in Title, Abstract or Keywords)
#12. (uptake in Title, Abstract or Keywords or reuptake in Title, Abstract or Keywords or re-uptake
in Title, Abstract or Keywords)
#13. inhib* in Title, Abstract or Keywords
#14. (#11 and #12 and #13)
#15. SSRI* in Title, Abstract or Keywords
#16. (alaproclat* in Title, Abstract or Keywords or cericlamin* in Title, Abstract or Keywords or
citalopram in Title, Abstract or Keywords or dapoxetin* in Title, Abstract or Keywords or
escitalopram in Title, Abstract or Keywords or femoxetin* in Title, Abstract or Keywords or
fluoxetin* in Title, Abstract or Keywords or fluvoxamin* in Title, Abstract or Keywords or paroxetin*
in Title, Abstract or Keywords or sertralin* in Title, Abstract or Keywords or trazodone in Title,
Abstract or Keywords or vilazodone in Title, Abstract or Keywords or zimelidine in Title, Abstract
or Keywords)
#17. (Celexa in Title, Abstract or Keywords or Cipramil in Title, Abstract or Keywords or Cipram in
Title, Abstract or Keywords or Recital in Title, Abstract or Keywords or Emocal in Title, Abstract or
Keywords or Dalsan in Title, Abstract or Keywords or Sepram in Title, Abstract or Keywords or
Seropram in Title, Abstract or Keywords or Citox in Title, Abstract or Keywords or Priligy in Title,
Abstract or Keywords or Lexapro in Title, Abstract or Keywords or Cipralex in Title, Abstract or
Keywords or Seroplex in Title, Abstract or Keywords or Esertia in Title, Abstract or Keywords or
Prozac in Title, Abstract or Keywords or Fontex in Title, Abstract or Keywords or Seromex in Title,
Abstract or Keywords or Seronil in Title, Abstract or Keywords or Sarafem in Title, Abstract or
Keywords or Ladose in Title, Abstract or Keywords or Motivest in Title, Abstract or Keywords or
Fluctin in Title, Abstract or Keywords or fluox in Title, Abstract or Keywords or Lovan in Title,
Abstract or Keywords or Luvox in Title, Abstract or Keywords or Fevarin in Title, Abstract or
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Keywords or Faverin in Title, Abstract or Keywords or Favoxil in Title, Abstract or Keywords or
Movox in Title, Abstract or Keywords or Paxil in Title, Abstract or Keywords or Seroxat in Title,
Abstract or Keywords or Sereupin in Title, Abstract or Keywords or Aropax in Title, Abstract or
Keywords or Deroxat in Title, Abstract or Keywords or Divarius in Title, Abstract or Keywords or
Rexetin in Title, Abstract or Keywords or Xetanor in Title, Abstract or Keywords or Paroxat in Title,
Abstract or Keywords or Loxamine in Title, Abstract or Keywords or Zoloft in Title, Abstract or
Keywords or Lustral in Title, Abstract or Keywords or Serlain in Title, Abstract or Keywords or
Asentra in Title, Abstract or Keywords)
#18. (#10 or #14 or #15 or #16 or #17)
#19. (#9 and #18).
MEDLINE (via Ovid) search strategy
1. cerebrovascular disorders/or exp basal ganglia cerebrovascular disease/or exp brain ischemia/or
exp carotid artery diseases/or exp intracranial arterial diseases/or exp “intracranial embolism and
thrombosis”/or exp intracranial hemorrhages/or stroke/or exp brain infarction/or vertebral
artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or
apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or
thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5
(haemorrhage$ or hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
5. hemiplegia/or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. exp Gait Disorders, Neurologic/
8. or/1-7
9. exp Serotonin Uptake Inhibitors/
10. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or
reuptake or re-uptake) adj5 inhib$).tw.
11. SSRI$1.tw.
12. (alaproclat$ or cericlamin$ or citalopram or dapoxetin$ or escitalopram or femoxetin$ or fluoxetin
$ or fluvoxamin$ or paroxetin$ or sertralin$ or trazodone or vilazodone or zimelidine).tw,nm.
13. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or
Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or
Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil
or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or
Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw,nm.
14. 9 or 10 or 11 or 12 or 13
15. 8 and 14
16. exp animals/not humans.sh.
17. 15 not 16
18. Randomized Controlled Trials as Topic/
19. random allocation/
20. Controlled Clinical Trials as Topic/
21. control groups/
22. clinical trials as topic/or clinical trials, phase i as topic/or clinical trials, phase ii as topic/or clinical
trials, phase iii as topic/or clinical trials, phase iv as topic/
23. Clinical Trials Data Monitoring Committees/
24. double-blind method/
25. single-blind method/
26. Placebos/
27. placebo effect/
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28. cross-over studies/
29. Multicenter Studies as Topic/
30. Therapies, Investigational/
31. Drug Evaluation/
32. Research Design/
33. Program Evaluation/
34. evaluation studies as topic/
35. randomized controlled trial.pt.
36. controlled clinical trial.pt.
37. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial
phase iv).pt.
38. multicenter study.pt.
39. (evaluation studies or comparative study).pt.
40. meta analysis.pt.
41. meta-analysis as topic/
42. random$.tw.
43. (controlled adj5 (trial$ or stud$)).tw.
44. (clinical$ adj5 trial$).tw.
45. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
46. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
47. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
48. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
49. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
50. (coin adj5 (flip or flipped or toss$)).tw.
51. latin square.tw.
52. versus.tw.
53. (cross-over or cross over or crossover).tw.
54. placebo$.tw.
55. sham.tw.
56. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
57. controls.tw.
58. (treatment$ adj6 order).tw.
59. (meta-analy$ or metaanaly$ or meta analy$ or systematic review or systematic overview).tw.
60. or/18-59
61. 17 and 60
EMBASE (via Ovid) search strategy
1. cerebrovascular disease/or basal ganglion hemorrhage/or exp brain hematoma/or exp brain
hemorrhage/or exp brain infarction/or exp brain ischemia/or exp carotid artery disease/or cerebral
artery disease/or cerebrovascular accident/or exp intracranial aneurysm/or exp occlusive
cerebrovascular disease/or stroke/
2. stroke unit/or stroke patient/
3. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or
apoplex$ or SAH).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or
thrombo$ or emboli$ or occlus$)).tw.
5. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5
(haemorrhage$ or hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
6. hemiparesis/or hemiplegia/or paresis/
7. (hemipleg$ or hemipar$ or paresis or paretic).tw.
8. or/1-7
9. exp serotonin uptake inhibitor/
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10. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or
reuptake or re-uptake) adj5 inhib$).tw.
11. SSRI$1.tw.
12. (alaproclat$ or cericlamin$ or citalopram or dapoxetin$ or escitalopram or femoxetin$ or
fluoxetin$ or fluvoxamin$ or paroxetin$ or sertralin$ or trazodone or vilazodone or zimelidine).tw.
13. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or
Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or
Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil
or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or
Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw,tn.
14. 9 or 10 or 11 or 12 or 13
15. 8 and 14
16. limit 15 to human
17. Randomized Controlled Trial/
18. Randomization/
19. Controlled Study/
20. control group/
21. clinical trial/or phase 1 clinical trial/or phase 2 clinical trial/or phase 3 clinical trial/or phase 4
clinical trial/or controlled clinical trial/
22. Double Blind Procedure/
23. Single Blind Procedure/or triple blind procedure/
24. placebo/
25. “types of study”/
26. research subject/
27. random$.tw.
28. (controlled adj5 (trial$ or stud$)).tw.
29. (clinical$ adj5 trial$).tw.
30. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
31. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
32. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
33. (coin adj5 (flip or flipped or toss$)).tw.
34. versus.tw.
35. placebo$.tw.
36. controls.tw.
37. or/17-36
38. 16 and 37
Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost)
search strategy
S23. S12 and S22
S22. S13 or S17 or S18 or S19 or S20 or S21
S21. AB Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or
Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or
Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin
or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or
Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra
S20. TI Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox
or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or
Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil
or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or
Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra
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S19. TI (alaproclat* or cericlamin* or citalopram or dapoxetin* or escitalopram or femoxetin* or
fluoxetin* or fluvoxamin* or paroxetin* or sertralin* or trazodone or vilazodone or zimelidine) OR AB
(alaproclat* or cericlamin* or citalopram or dapoxetin* or escitalopram or femoxetin* or fluoxetin* or
fluvoxamin* or paroxetin* or sertralin* or trazodone or vilazodone or zimelidine)
S18. TI SSRI* OR AB SSRI*
S17. S14 and S15 and S16
S16. TI inhib* OR AB inhib*
S15. TI (uptake or reuptake or re-uptake) OR AB (uptake or reuptake or re-uptake)
S14. TI (serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) OR AB
(serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine)
S13. (MH “Serotonin Uptake Inhibitors+”)
S12. S1 or S2 or S3 or S6 or S9 or S10 or S11
S11. TI (hemipleg* or hemipar* or paresis or paretic) or AB (hemipleg* or hemipar* or paresis
or paretic)
S10. (MH “Hemiplegia”)
S9. S7 and S8
S8. TI (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*) or AB (haemorrhage*
or hemorrhage* or haematoma* or hematoma* or bleed*)
S7. TI (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) or AB (brain* or
cerebr* or cerebell* or intracerebral or intracranial or subarachnoid)
S6. S4 and S5
S5. TI (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus*) or AB (ischemi* or
ischaemi* or infarct* or thrombo* or emboli* or occlus*)
S4. TI (brain* or cerebr* or cerebell* or intracran* or intracerebral) or AB (brain* or cerebr* or
cerebell* or intracran* or intracerebral)
S3. TI (stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or
apoplex or SAH) or AB (stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or
cerebral vasc or cva or apoplex or SAH)
S2. (MH “Stroke Patients”) OR (MH “Stroke Units”)
S1. (MH “Cerebrovascular Disorders”) OR (MH “Basal Ganglia Cerebrovascular Disease+”) OR (MH
“Carotid Artery Diseases+”) OR (MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR
(MH “Intracranial Arterial Diseases+”) OR (MH “Intracranial Embolism and Thrombosis”) OR (MH
“Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral Artery Dissections”)
Allied and Complementary Medicine (AMED) (via Ovid) search strategy
1. cerebrovascular disorders/or cerebral hemorrhage/or cerebral infarction/or cerebral ischemia/or
cerebrovascular accident/or stroke/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or
apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or
thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5
(haemorrhage$ or hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
5. hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. or/1-6
8. antidepressive agents/
9. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or
reuptake or re-uptake) adj5 inhib$).tw.
10. SSRI$1.tw.
11. (alaproclat$ or cericlamin$ or citalopram or dapoxetin$ or escitalopram or femoxetin$ or
fluoxetin$ or fluvoxamin$ or paroxetin$ or sertralin$ or trazodone or vilazodone or zimelidine).tw.
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12. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or
Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or
Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil
or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or
Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
PsycINFO (via Ovid) search strategy
1. cerebrovascular disorders/or cerebral hemorrhage/or exp cerebral ischemia/or cerebral small
vessel disease/or cerebrovascular accidents/or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or
apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or
thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5
(haemorrhage$ or hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
5. (hemipleg$ or hemipar$ or paresis or paretic).tw.
6. hemiparesis/or hemiplegia/
7. or/1-6
8. exp serotonin reuptake inhibitors/
9. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or
reuptake or re-uptake) adj5 inhib$).tw.
10. SSRI$1.tw.
11. (alaproclat$ or cericlamin$ or citalopram or dapoxetin$ or escitalopram or femoxetin$ or
fluoxetin$ or fluvoxamin$ or paroxetin$ or sertralin$ or trazodone or vilazodone or zimelidine).tw.
12. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or
Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or
Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil
or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or
Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
Search strategy for the trial registers
Patient: stroke.
Intervention: alaproclate OR cericlamineOR citalopram OR clomipramine OR dapoxetine OR
etoperidone OR femoxetine OR fenfluramine OR fluoxetine OR fluvoxamine OR norfenfluramine OR
paroxetine OR sertraline OR trazodone OR vilazodone OR zimelidine.
Comparison: placebo.
Trial status: ongoing OR Recruiting OR Not yet recruiting OR Active.
Age: adult OR older adult.
Methods: Randomised Controlled Study.
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